JP2011523400A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011523400A5 JP2011523400A5 JP2011507576A JP2011507576A JP2011523400A5 JP 2011523400 A5 JP2011523400 A5 JP 2011523400A5 JP 2011507576 A JP2011507576 A JP 2011507576A JP 2011507576 A JP2011507576 A JP 2011507576A JP 2011523400 A5 JP2011523400 A5 JP 2011523400A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- chain variable
- variable domain
- targeting
- cdr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000008685 targeting Effects 0.000 claims 521
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 196
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 196
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 196
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 196
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 196
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 192
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 192
- 102000014914 Carrier Proteins Human genes 0.000 claims 98
- 108091008324 binding proteins Proteins 0.000 claims 98
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims 67
- 101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 claims 67
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims 67
- 102100025947 Insulin-like growth factor II Human genes 0.000 claims 67
- 101150062285 PGF gene Proteins 0.000 claims 49
- 102100035194 Placenta growth factor Human genes 0.000 claims 49
- 238000010494 dissociation reaction Methods 0.000 claims 48
- 230000005593 dissociations Effects 0.000 claims 48
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 48
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 claims 46
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims 46
- 238000000034 method Methods 0.000 claims 32
- 229920001184 polypeptide Polymers 0.000 claims 24
- 102000004196 processed proteins & peptides Human genes 0.000 claims 24
- 108090000765 processed proteins & peptides Proteins 0.000 claims 24
- 239000012634 fragment Substances 0.000 claims 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 22
- 102000004207 Neuropilin-1 Human genes 0.000 claims 21
- 108090000772 Neuropilin-1 Proteins 0.000 claims 21
- 210000004027 cell Anatomy 0.000 claims 19
- 201000010099 disease Diseases 0.000 claims 18
- 238000013357 binding ELISA Methods 0.000 claims 16
- 208000011580 syndromic disease Diseases 0.000 claims 16
- 230000001154 acute effect Effects 0.000 claims 12
- 208000019693 Lung disease Diseases 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 10
- 230000001684 chronic effect Effects 0.000 claims 9
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 8
- 230000001363 autoimmune Effects 0.000 claims 8
- 210000000056 organ Anatomy 0.000 claims 8
- 206010020751 Hypersensitivity Diseases 0.000 claims 7
- 206010061218 Inflammation Diseases 0.000 claims 7
- 206010052779 Transplant rejections Diseases 0.000 claims 7
- 230000001225 therapeutic effect Effects 0.000 claims 7
- 201000004624 Dermatitis Diseases 0.000 claims 6
- 230000004054 inflammatory process Effects 0.000 claims 6
- 238000011321 prophylaxis Methods 0.000 claims 6
- 208000026935 allergic disease Diseases 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 5
- 208000006454 hepatitis Diseases 0.000 claims 5
- 231100000283 hepatitis Toxicity 0.000 claims 5
- 208000015181 infectious disease Diseases 0.000 claims 5
- 230000002757 inflammatory effect Effects 0.000 claims 5
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 4
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 4
- 102000004127 Cytokines Human genes 0.000 claims 4
- 108090000695 Cytokines Proteins 0.000 claims 4
- 206010040047 Sepsis Diseases 0.000 claims 4
- 206010047115 Vasculitis Diseases 0.000 claims 4
- 206010003119 arrhythmia Diseases 0.000 claims 4
- 206010003246 arthritis Diseases 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 208000030507 AIDS Diseases 0.000 claims 3
- 208000026872 Addison Disease Diseases 0.000 claims 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 3
- 206010010741 Conjunctivitis Diseases 0.000 claims 3
- 206010015150 Erythema Diseases 0.000 claims 3
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 3
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 3
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 208000002193 Pain Diseases 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 206010034277 Pemphigoid Diseases 0.000 claims 3
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 3
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 3
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 3
- 208000031845 Pernicious anaemia Diseases 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 3
- 206010039710 Scleroderma Diseases 0.000 claims 3
- 230000007815 allergy Effects 0.000 claims 3
- 208000007502 anemia Diseases 0.000 claims 3
- -1 antibiotic Substances 0.000 claims 3
- 230000006793 arrhythmia Effects 0.000 claims 3
- 208000006673 asthma Diseases 0.000 claims 3
- 208000010668 atopic eczema Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 3
- 208000018631 connective tissue disease Diseases 0.000 claims 3
- 239000002872 contrast media Substances 0.000 claims 3
- 239000002254 cytotoxic agent Substances 0.000 claims 3
- 229940127089 cytotoxic agent Drugs 0.000 claims 3
- 231100000599 cytotoxic agent Toxicity 0.000 claims 3
- 230000007850 degeneration Effects 0.000 claims 3
- 231100000321 erythema Toxicity 0.000 claims 3
- 230000002538 fungal effect Effects 0.000 claims 3
- 208000026278 immune system disease Diseases 0.000 claims 3
- 238000003018 immunoassay Methods 0.000 claims 3
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 3
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 3
- 230000003902 lesion Effects 0.000 claims 3
- 208000019423 liver disease Diseases 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 208000010125 myocardial infarction Diseases 0.000 claims 3
- 201000001119 neuropathy Diseases 0.000 claims 3
- 230000007823 neuropathy Effects 0.000 claims 3
- 230000000414 obstructive effect Effects 0.000 claims 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 210000003491 skin Anatomy 0.000 claims 3
- 238000002054 transplantation Methods 0.000 claims 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 2
- 206010003591 Ataxia Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 206010003645 Atopy Diseases 0.000 claims 2
- 208000000659 Autoimmune lymphoproliferative syndrome Diseases 0.000 claims 2
- 208000015879 Cerebellar disease Diseases 0.000 claims 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 206010056370 Congestive cardiomyopathy Diseases 0.000 claims 2
- 208000016192 Demyelinating disease Diseases 0.000 claims 2
- 206010012442 Dermatitis contact Diseases 0.000 claims 2
- 208000017701 Endocrine disease Diseases 0.000 claims 2
- 241000588724 Escherichia coli Species 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 208000007465 Giant cell arteritis Diseases 0.000 claims 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims 2
- 208000001204 Hashimoto Disease Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 2
- 208000036066 Hemophagocytic Lymphohistiocytosis Diseases 0.000 claims 2
- 208000032843 Hemorrhage Diseases 0.000 claims 2
- 241000238631 Hexapoda Species 0.000 claims 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 2
- 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 claims 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 2
- 208000016604 Lyme disease Diseases 0.000 claims 2
- 201000009906 Meningitis Diseases 0.000 claims 2
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims 2
- 208000000112 Myalgia Diseases 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 208000009525 Myocarditis Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 2
- 208000003435 Optic Neuritis Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 241000721454 Pemphigus Species 0.000 claims 2
- 206010035664 Pneumonia Diseases 0.000 claims 2
- 206010036105 Polyneuropathy Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 2
- 206010037549 Purpura Diseases 0.000 claims 2
- 241001672981 Purpura Species 0.000 claims 2
- 208000003782 Raynaud disease Diseases 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- 208000025747 Rheumatic disease Diseases 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- 206010062164 Seronegative arthritis Diseases 0.000 claims 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 2
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 claims 2
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 208000024780 Urticaria Diseases 0.000 claims 2
- 206010046851 Uveitis Diseases 0.000 claims 2
- 208000004631 alopecia areata Diseases 0.000 claims 2
- 230000003444 anaesthetic effect Effects 0.000 claims 2
- 208000003455 anaphylaxis Diseases 0.000 claims 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 2
- 210000004102 animal cell Anatomy 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 2
- 230000003143 atherosclerotic effect Effects 0.000 claims 2
- 230000005784 autoimmunity Effects 0.000 claims 2
- 208000034158 bleeding Diseases 0.000 claims 2
- 230000000740 bleeding effect Effects 0.000 claims 2
- 230000002490 cerebral effect Effects 0.000 claims 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 2
- 201000001981 dermatomyositis Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 206010014665 endocarditis Diseases 0.000 claims 2
- 208000030172 endocrine system disease Diseases 0.000 claims 2
- 210000003527 eukaryotic cell Anatomy 0.000 claims 2
- 210000002216 heart Anatomy 0.000 claims 2
- 230000009033 hematopoietic malignancy Effects 0.000 claims 2
- 230000002458 infectious effect Effects 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 2
- 206010028417 myasthenia gravis Diseases 0.000 claims 2
- 210000005036 nerve Anatomy 0.000 claims 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 208000015124 ovarian disease Diseases 0.000 claims 2
- 201000004535 ovarian dysfunction Diseases 0.000 claims 2
- 231100000543 ovarian dysfunction Toxicity 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 230000002093 peripheral effect Effects 0.000 claims 2
- 208000005987 polymyositis Diseases 0.000 claims 2
- 210000001236 prokaryotic cell Anatomy 0.000 claims 2
- 210000002307 prostate Anatomy 0.000 claims 2
- 208000020016 psychiatric disease Diseases 0.000 claims 2
- 230000002685 pulmonary effect Effects 0.000 claims 2
- 208000002574 reactive arthritis Diseases 0.000 claims 2
- 230000000552 rheumatic effect Effects 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims 2
- 201000005671 spondyloarthropathy Diseases 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 206010043207 temporal arteritis Diseases 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 210000005253 yeast cell Anatomy 0.000 claims 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims 1
- 229930182837 (R)-adrenaline Natural products 0.000 claims 1
- 208000023769 AA amyloidosis Diseases 0.000 claims 1
- 206010065040 AIDS dementia complex Diseases 0.000 claims 1
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 1
- 206010000830 Acute leukaemia Diseases 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 206010002329 Aneurysm Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010002388 Angina unstable Diseases 0.000 claims 1
- 208000032467 Aplastic anaemia Diseases 0.000 claims 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 claims 1
- 200000000007 Arterial disease Diseases 0.000 claims 1
- 206010003226 Arteriovenous fistula Diseases 0.000 claims 1
- 206010053555 Arthritis bacterial Diseases 0.000 claims 1
- 206010003267 Arthritis reactive Diseases 0.000 claims 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims 1
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 1
- 206010003662 Atrial flutter Diseases 0.000 claims 1
- 206010003671 Atrioventricular Block Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010055128 Autoimmune neutropenia Diseases 0.000 claims 1
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 claims 1
- 208000022106 Autoimmune polyendocrinopathy type 2 Diseases 0.000 claims 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims 1
- 241000271566 Aves Species 0.000 claims 1
- 208000037157 Azotemia Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 206010006448 Bronchiolitis Diseases 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 208000000135 Cardiovascular Syphilis Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010008025 Cerebellar ataxia Diseases 0.000 claims 1
- 206010008190 Cerebrovascular accident Diseases 0.000 claims 1
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 claims 1
- 241000606161 Chlamydia Species 0.000 claims 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 1
- 206010008635 Cholestasis Diseases 0.000 claims 1
- 206010008748 Chorea Diseases 0.000 claims 1
- 206010008909 Chronic Hepatitis Diseases 0.000 claims 1
- 208000008818 Chronic Mucocutaneous Candidiasis Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 201000003874 Common Variable Immunodeficiency Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 206010010941 Coombs positive haemolytic anaemia Diseases 0.000 claims 1
- 102000012437 Copper-Transporting ATPases Human genes 0.000 claims 1
- 206010052895 Coronary artery insufficiency Diseases 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010011703 Cyanosis Diseases 0.000 claims 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- 206010011732 Cyst Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010011878 Deafness Diseases 0.000 claims 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 claims 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims 1
- 206010012310 Dengue fever Diseases 0.000 claims 1
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 claims 1
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 claims 1
- 208000002251 Dissecting Aneurysm Diseases 0.000 claims 1
- 102000015554 Dopamine receptor Human genes 0.000 claims 1
- 108050004812 Dopamine receptor Proteins 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 206010072268 Drug-induced liver injury Diseases 0.000 claims 1
- 206010058314 Dysplasia Diseases 0.000 claims 1
- 206010014612 Encephalitis viral Diseases 0.000 claims 1
- 208000004145 Endometritis Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 206010015108 Epstein-Barr virus infection Diseases 0.000 claims 1
- 102000003951 Erythropoietin Human genes 0.000 claims 1
- 108090000394 Erythropoietin Proteins 0.000 claims 1
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 claims 1
- 208000035366 Familial hemophagocytic lymphohistiocytosis Diseases 0.000 claims 1
- 208000002633 Febrile Neutropenia Diseases 0.000 claims 1
- 208000007984 Female Infertility Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000024412 Friedreich ataxia Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 206010058872 Fungal sepsis Diseases 0.000 claims 1
- 201000000628 Gas Gangrene Diseases 0.000 claims 1
- 206010018498 Goitre Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010018691 Granuloma Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 102000018997 Growth Hormone Human genes 0.000 claims 1
- 108010051696 Growth Hormone Proteins 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 206010019315 Heart transplant rejection Diseases 0.000 claims 1
- 208000018565 Hemochromatosis Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 206010019755 Hepatitis chronic active Diseases 0.000 claims 1
- 206010019786 Hepatitis non-A non-B Diseases 0.000 claims 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims 1
- 208000002291 Histiocytic Sarcoma Diseases 0.000 claims 1
- 208000032672 Histiocytosis haematophagic Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000037147 Hypercalcaemia Diseases 0.000 claims 1
- 208000019758 Hypergammaglobulinemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010020850 Hyperthyroidism Diseases 0.000 claims 1
- 208000013016 Hypoglycemia Diseases 0.000 claims 1
- 208000000038 Hypoparathyroidism Diseases 0.000 claims 1
- 208000016300 Idiopathic chronic eosinophilic pneumonia Diseases 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 208000004575 Infectious Arthritis Diseases 0.000 claims 1
- 206010021928 Infertility female Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000003618 Intervertebral Disc Displacement Diseases 0.000 claims 1
- 206010050296 Intervertebral disc protrusion Diseases 0.000 claims 1
- 206010058142 Intestine transplant rejection Diseases 0.000 claims 1
- 206010022941 Iridocyclitis Diseases 0.000 claims 1
- 208000032382 Ischaemic stroke Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000011200 Kawasaki disease Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 208000006264 Korsakoff syndrome Diseases 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 claims 1
- 241000589248 Legionella Species 0.000 claims 1
- 208000007764 Legionnaires' Disease Diseases 0.000 claims 1
- 208000004554 Leishmaniasis Diseases 0.000 claims 1
- 206010024229 Leprosy Diseases 0.000 claims 1
- 206010024380 Leukoderma Diseases 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 208000012309 Linear IgA disease Diseases 0.000 claims 1
- 206010024558 Lip oedema Diseases 0.000 claims 1
- 208000007021 Lipedema Diseases 0.000 claims 1
- 206010067125 Liver injury Diseases 0.000 claims 1
- 206010024715 Liver transplant rejection Diseases 0.000 claims 1
- 206010025282 Lymphoedema Diseases 0.000 claims 1
- 208000035809 Lymphohistiocytosis Diseases 0.000 claims 1
- 206010025421 Macule Diseases 0.000 claims 1
- 208000007466 Male Infertility Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 206010060880 Monoclonal gammopathy Diseases 0.000 claims 1
- 208000019430 Motor disease Diseases 0.000 claims 1
- 208000003423 Mucocele Diseases 0.000 claims 1
- 206010028080 Mucocutaneous candidiasis Diseases 0.000 claims 1
- 208000034486 Multi-organ failure Diseases 0.000 claims 1
- 208000010718 Multiple Organ Failure Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 241000545499 Mycobacterium avium-intracellulare Species 0.000 claims 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 201000002481 Myositis Diseases 0.000 claims 1
- 206010028665 Myxoedema Diseases 0.000 claims 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 206010029240 Neuritis Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010061876 Obstruction Diseases 0.000 claims 1
- 206010058461 Orchitis noninfective Diseases 0.000 claims 1
- 208000003076 Osteolysis Diseases 0.000 claims 1
- 206010031252 Osteomyelitis Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010053869 POEMS syndrome Diseases 0.000 claims 1
- 206010049169 Pancreas transplant rejection Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010033647 Pancreatitis acute Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 claims 1
- 208000008223 Pemphigoid Gestationis Diseases 0.000 claims 1
- 201000011152 Pemphigus Diseases 0.000 claims 1
- 208000025584 Pericardial disease Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000005384 Pneumocystis Pneumonia Diseases 0.000 claims 1
- 206010073755 Pneumocystis jirovecii pneumonia Diseases 0.000 claims 1
- 208000005374 Poisoning Diseases 0.000 claims 1
- 206010036030 Polyarthritis Diseases 0.000 claims 1
- 206010065159 Polychondritis Diseases 0.000 claims 1
- 206010057244 Post viral fatigue syndrome Diseases 0.000 claims 1
- 208000023146 Pre-existing disease Diseases 0.000 claims 1
- 208000002500 Primary Ovarian Insufficiency Diseases 0.000 claims 1
- 206010052381 Primary adrenal insufficiency Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 208000012287 Prolapse Diseases 0.000 claims 1
- 208000033526 Proximal spinal muscular atrophy type 3 Diseases 0.000 claims 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 208000005587 Refsum Disease Diseases 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000033626 Renal failure acute Diseases 0.000 claims 1
- 201000003099 Renovascular Hypertension Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010038748 Restrictive cardiomyopathy Diseases 0.000 claims 1
- 206010038910 Retinitis Diseases 0.000 claims 1
- 206010038915 Retinitis viral Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010039094 Rhinitis perennial Diseases 0.000 claims 1
- 241000159610 Roya <green alga> Species 0.000 claims 1
- 241000607142 Salmonella Species 0.000 claims 1
- 241000876474 Sapho Species 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000008765 Sciatica Diseases 0.000 claims 1
- 206010039705 Scleritis Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 206010039807 Secondary adrenocortical insufficiency Diseases 0.000 claims 1
- 206010039811 Secondary amyloidosis Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 208000009714 Severe Dengue Diseases 0.000 claims 1
- 208000003954 Spinal Muscular Atrophies of Childhood Diseases 0.000 claims 1
- 206010041591 Spinal osteoarthritis Diseases 0.000 claims 1
- 208000010112 Spinocerebellar Degenerations Diseases 0.000 claims 1
- 208000006045 Spondylarthropathies Diseases 0.000 claims 1
- 208000032509 Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum Diseases 0.000 claims 1
- 208000007107 Stomach Ulcer Diseases 0.000 claims 1
- 206010061372 Streptococcal infection Diseases 0.000 claims 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 claims 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 claims 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 208000001871 Tachycardia Diseases 0.000 claims 1
- 241001275831 Tanais Species 0.000 claims 1
- 206010043189 Telangiectasia Diseases 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 206010044223 Toxic epidermal necrolysis Diseases 0.000 claims 1
- 206010044248 Toxic shock syndrome Diseases 0.000 claims 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims 1
- 241000223996 Toxoplasma Species 0.000 claims 1
- 102100040247 Tumor necrosis factor Human genes 0.000 claims 1
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 claims 1
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 206010053614 Type III immune complex mediated reaction Diseases 0.000 claims 1
- 208000007814 Unstable Angina Diseases 0.000 claims 1
- 208000001445 Uveomeningoencephalitic Syndrome Diseases 0.000 claims 1
- 206010046996 Varicose vein Diseases 0.000 claims 1
- 206010047249 Venous thrombosis Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 201000008485 Wernicke-Korsakoff syndrome Diseases 0.000 claims 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 1
- 208000018839 Wilson disease Diseases 0.000 claims 1
- 241000607734 Yersinia <bacteria> Species 0.000 claims 1
- 208000004622 abetalipoproteinemia Diseases 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 201000011040 acute kidney failure Diseases 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 201000003229 acute pancreatitis Diseases 0.000 claims 1
- 208000012998 acute renal failure Diseases 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 230000001780 adrenocortical effect Effects 0.000 claims 1
- 208000030597 adult Refsum disease Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 208000002029 allergic contact dermatitis Diseases 0.000 claims 1
- 208000030961 allergic reaction Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 claims 1
- 150000001413 amino acids Chemical group 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 239000003263 anabolic agent Substances 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 claims 1
- 230000036783 anaphylactic response Effects 0.000 claims 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 210000002226 anterior horn cell Anatomy 0.000 claims 1
- 201000004612 anterior uveitis Diseases 0.000 claims 1
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 1
- 230000003092 anti-cytokine Effects 0.000 claims 1
- 230000001430 anti-depressive effect Effects 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 230000002682 anti-psoriatic effect Effects 0.000 claims 1
- 230000000561 anti-psychotic effect Effects 0.000 claims 1
- 230000009227 antibody-mediated cytotoxicity Effects 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 239000003080 antimitotic agent Substances 0.000 claims 1
- 239000003435 antirheumatic agent Substances 0.000 claims 1
- 210000000702 aorta abdominal Anatomy 0.000 claims 1
- 206010002895 aortic dissection Diseases 0.000 claims 1
- 230000001640 apoptogenic effect Effects 0.000 claims 1
- 208000037849 arterial hypertension Diseases 0.000 claims 1
- 208000021328 arterial occlusion Diseases 0.000 claims 1
- 206010003230 arteritis Diseases 0.000 claims 1
- 230000002917 arthritic effect Effects 0.000 claims 1
- 206010003549 asthenia Diseases 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 206010003668 atrial tachycardia Diseases 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 201000009780 autoimmune polyendocrine syndrome type 2 Diseases 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 208000010928 autoimmune thyroid disease Diseases 0.000 claims 1
- 201000003308 autosomal dominant familial periodic fever Diseases 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 208000018300 basal ganglia disease Diseases 0.000 claims 1
- 229940125388 beta agonist Drugs 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 208000010217 blepharitis Diseases 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 201000009267 bronchiectasis Diseases 0.000 claims 1
- 208000000594 bullous pemphigoid Diseases 0.000 claims 1
- 210000004375 bundle of his Anatomy 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 230000002612 cardiopulmonary effect Effects 0.000 claims 1
- 210000000845 cartilage Anatomy 0.000 claims 1
- 208000036319 cervical spondylosis Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 230000007870 cholestasis Effects 0.000 claims 1
- 231100000359 cholestasis Toxicity 0.000 claims 1
- 201000009323 chronic eosinophilic pneumonia Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 230000002596 correlated effect Effects 0.000 claims 1
- 230000001054 cortical effect Effects 0.000 claims 1
- 230000002594 corticospinal effect Effects 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 230000000139 costimulatory effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 229930182912 cyclosporin Natural products 0.000 claims 1
- 208000031513 cyst Diseases 0.000 claims 1
- 201000003146 cystitis Diseases 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 206010061811 demyelinating polyneuropathy Diseases 0.000 claims 1
- 201000002950 dengue hemorrhagic fever Diseases 0.000 claims 1
- 201000011304 dilated cardiomyopathy 1A Diseases 0.000 claims 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000008865 drug-induced hepatitis Diseases 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 208000002296 eclampsia Diseases 0.000 claims 1
- 201000002491 encephalomyelitis Diseases 0.000 claims 1
- 230000002124 endocrine Effects 0.000 claims 1
- 206010014801 endophthalmitis Diseases 0.000 claims 1
- 210000002409 epiglottis Anatomy 0.000 claims 1
- 229960005139 epinephrine Drugs 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 claims 1
- 229940105423 erythropoietin Drugs 0.000 claims 1
- 238000011156 evaluation Methods 0.000 claims 1
- 201000010934 exostosis Diseases 0.000 claims 1
- 201000008825 fibrosarcoma of bone Diseases 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 201000005917 gastric ulcer Diseases 0.000 claims 1
- 201000003872 goiter Diseases 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 239000000122 growth hormone Substances 0.000 claims 1
- 238000001631 haemodialysis Methods 0.000 claims 1
- 201000009277 hairy cell leukemia Diseases 0.000 claims 1
- 230000010370 hearing loss Effects 0.000 claims 1
- 231100000888 hearing loss Toxicity 0.000 claims 1
- 208000016354 hearing loss disease Diseases 0.000 claims 1
- 201000010235 heart cancer Diseases 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 208000024348 heart neoplasm Diseases 0.000 claims 1
- 208000018578 heart valve disease Diseases 0.000 claims 1
- 230000000322 hemodialysis Effects 0.000 claims 1
- 208000007475 hemolytic anemia Diseases 0.000 claims 1
- 208000014752 hemophagocytic syndrome Diseases 0.000 claims 1
- 231100000753 hepatic injury Toxicity 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 208000013403 hyperactivity Diseases 0.000 claims 1
- 230000000148 hypercalcaemia Effects 0.000 claims 1
- 208000030915 hypercalcemia disease Diseases 0.000 claims 1
- 230000001660 hyperkinetic effect Effects 0.000 claims 1
- 201000010930 hyperostosis Diseases 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 230000002218 hypoglycaemic effect Effects 0.000 claims 1
- 230000003483 hypokinetic effect Effects 0.000 claims 1
- 208000003532 hypothyroidism Diseases 0.000 claims 1
- 230000002989 hypothyroidism Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 201000008319 inclusion body myositis Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000028709 inflammatory response Effects 0.000 claims 1
- 208000037797 influenza A Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 1
- 208000028774 intestinal disease Diseases 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000007914 intraventricular administration Methods 0.000 claims 1
- 230000005865 ionizing radiation Effects 0.000 claims 1
- 201000004614 iritis Diseases 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 208000023589 ischemic disease Diseases 0.000 claims 1
- 230000000366 juvenile effect Effects 0.000 claims 1
- 201000004815 juvenile spinal muscular atrophy Diseases 0.000 claims 1
- 206010023332 keratitis Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 201000002364 leukopenia Diseases 0.000 claims 1
- 231100001022 leukopenia Toxicity 0.000 claims 1
- 210000004558 lewy body Anatomy 0.000 claims 1
- 239000003589 local anesthetic agent Substances 0.000 claims 1
- 208000002502 lymphedema Diseases 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 230000000527 lymphocytic effect Effects 0.000 claims 1
- 208000029791 lytic metastatic bone lesion Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 201000006812 malignant histiocytosis Diseases 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 210000002418 meninge Anatomy 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 206010063344 microscopic polyangiitis Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 230000002438 mitochondrial effect Effects 0.000 claims 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims 1
- 208000017972 multifocal atrial tachycardia Diseases 0.000 claims 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims 1
- 230000020763 muscle atrophy Effects 0.000 claims 1
- 201000000585 muscular atrophy Diseases 0.000 claims 1
- 239000003158 myorelaxant agent Substances 0.000 claims 1
- 208000003786 myxedema Diseases 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 208000009928 nephrosis Diseases 0.000 claims 1
- 231100001027 nephrosis Toxicity 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000001272 neurogenic effect Effects 0.000 claims 1
- 239000000842 neuromuscular blocking agent Substances 0.000 claims 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims 1
- 230000003071 parasitic effect Effects 0.000 claims 1
- 230000000849 parathyroid Effects 0.000 claims 1
- 230000001314 paroxysmal effect Effects 0.000 claims 1
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 1
- 230000010412 perfusion Effects 0.000 claims 1
- 206010034674 peritonitis Diseases 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 claims 1
- 208000015385 phacoanaphylactic uveitis Diseases 0.000 claims 1
- 208000001297 phlebitis Diseases 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 201000000317 pneumocystosis Diseases 0.000 claims 1
- 231100000572 poisoning Toxicity 0.000 claims 1
- 230000000607 poisoning effect Effects 0.000 claims 1
- 201000006292 polyarteritis nodosa Diseases 0.000 claims 1
- 208000030428 polyarticular arthritis Diseases 0.000 claims 1
- 208000019629 polyneuritis Diseases 0.000 claims 1
- 230000007824 polyneuropathy Effects 0.000 claims 1
- 229920001296 polysiloxane Polymers 0.000 claims 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 1
- 206010036601 premature menopause Diseases 0.000 claims 1
- 201000008312 primary pulmonary hypertension Diseases 0.000 claims 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 239000012217 radiopharmaceutical Substances 0.000 claims 1
- 229940121896 radiopharmaceutical Drugs 0.000 claims 1
- 230000002799 radiopharmaceutical effect Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 208000004124 rheumatic heart disease Diseases 0.000 claims 1
- 229960004889 salicylic acid Drugs 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 230000037390 scarring Effects 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 1
- 208000023087 secondary adrenal insufficiency Diseases 0.000 claims 1
- 239000000932 sedative agent Substances 0.000 claims 1
- 230000001624 sedative effect Effects 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 201000001223 septic arthritis Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 208000002320 spinal muscular atrophy Diseases 0.000 claims 1
- 208000005801 spondylosis Diseases 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 201000004595 synovitis Diseases 0.000 claims 1
- 208000020408 systemic-onset juvenile idiopathic arthritis Diseases 0.000 claims 1
- 230000006794 tachycardia Effects 0.000 claims 1
- 208000009056 telangiectasis Diseases 0.000 claims 1
- 230000002381 testicular Effects 0.000 claims 1
- 206010043554 thrombocytopenia Diseases 0.000 claims 1
- 230000002537 thrombolytic effect Effects 0.000 claims 1
- 210000001541 thymus gland Anatomy 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 208000009174 transverse myelitis Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims 1
- 208000025883 type III hypersensitivity disease Diseases 0.000 claims 1
- 230000005951 type IV hypersensitivity Effects 0.000 claims 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 claims 1
- 208000009852 uremia Diseases 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 230000002485 urinary effect Effects 0.000 claims 1
- 208000027185 varicose disease Diseases 0.000 claims 1
- 230000003156 vasculitic effect Effects 0.000 claims 1
- 238000007879 vasectomy Methods 0.000 claims 1
- 208000037997 venous disease Diseases 0.000 claims 1
- 230000003519 ventilatory effect Effects 0.000 claims 1
- 208000003663 ventricular fibrillation Diseases 0.000 claims 1
- 208000018464 vernal keratoconjunctivitis Diseases 0.000 claims 1
- 201000002498 viral encephalitis Diseases 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12583408P | 2008-04-29 | 2008-04-29 | |
| US61/125,834 | 2008-04-29 | ||
| US13428308P | 2008-07-08 | 2008-07-08 | |
| US61/134,283 | 2008-07-08 | ||
| US19719108P | 2008-10-23 | 2008-10-23 | |
| US61/197,191 | 2008-10-23 | ||
| US19900908P | 2008-11-12 | 2008-11-12 | |
| US61/199,009 | 2008-11-12 | ||
| PCT/US2009/041945 WO2009134776A2 (en) | 2008-04-29 | 2009-04-28 | Dual variable domain immunoglobulins and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014099291A Division JP2014193170A (ja) | 2008-04-29 | 2014-05-13 | 二重可変ドメイン免疫グロブリン及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011523400A JP2011523400A (ja) | 2011-08-11 |
| JP2011523400A5 true JP2011523400A5 (enExample) | 2012-08-16 |
| JP5646457B2 JP5646457B2 (ja) | 2014-12-24 |
Family
ID=41255726
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011507576A Expired - Fee Related JP5646457B2 (ja) | 2008-04-29 | 2009-04-28 | 二重可変ドメイン免疫グロブリン及びその使用 |
| JP2014099291A Pending JP2014193170A (ja) | 2008-04-29 | 2014-05-13 | 二重可変ドメイン免疫グロブリン及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014099291A Pending JP2014193170A (ja) | 2008-04-29 | 2014-05-13 | 二重可変ドメイン免疫グロブリン及びその使用 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US9029508B2 (enExample) |
| EP (2) | EP2282769A4 (enExample) |
| JP (2) | JP5646457B2 (enExample) |
| KR (1) | KR20110014607A (enExample) |
| CN (1) | CN102076355B (enExample) |
| AR (1) | AR071526A1 (enExample) |
| AU (1) | AU2009241589B2 (enExample) |
| BR (1) | BRPI0910482A2 (enExample) |
| CA (1) | CA2722466A1 (enExample) |
| CL (1) | CL2009001033A1 (enExample) |
| CO (1) | CO6331296A2 (enExample) |
| CR (1) | CR11795A (enExample) |
| DO (1) | DOP2010000325A (enExample) |
| EC (1) | ECSP10010580A (enExample) |
| IL (1) | IL208693A0 (enExample) |
| MX (1) | MX2010011955A (enExample) |
| NZ (1) | NZ588554A (enExample) |
| PE (1) | PE20091845A1 (enExample) |
| SG (1) | SG190572A1 (enExample) |
| TW (1) | TW200950805A (enExample) |
| UY (1) | UY31792A (enExample) |
| WO (1) | WO2009134776A2 (enExample) |
Families Citing this family (171)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009519983A (ja) | 2005-12-20 | 2009-05-21 | アラーナ・テラピューティクス・リミテッド | 部分的な新世界ザル結合領域を有するキメラ抗体 |
| EP2009101B1 (en) | 2006-03-31 | 2017-10-25 | Chugai Seiyaku Kabushiki Kaisha | Antibody modification method for purifying bispecific antibody |
| US7750124B2 (en) | 2006-09-29 | 2010-07-06 | Oncomed Pharmaceuticals, Inc. | Anti-human DLL4 antibodies and compositions |
| ES2742268T3 (es) | 2007-12-26 | 2020-02-13 | Xencor Inc | Variantes de Fc con unión alterada a FcRn |
| CN102076355B (zh) * | 2008-04-29 | 2014-05-07 | Abbvie公司 | 双重可变结构域免疫球蛋白及其用途 |
| US9513300B2 (en) * | 2008-05-05 | 2016-12-06 | Cornell University | Determination of serum anti-mullerian hormone as a diagnostic test for spay in companion animals |
| AU2009256246B2 (en) * | 2008-06-03 | 2013-07-18 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| SG191639A1 (en) * | 2008-06-03 | 2013-07-31 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| AU2009268585C1 (en) | 2008-07-08 | 2014-10-02 | Abbvie Inc. | Prostaglandin E2 dual variable domain immunoglobulins and uses thereof |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| SG171812A1 (en) * | 2008-12-04 | 2011-07-28 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| PE20160653A1 (es) | 2009-03-05 | 2016-07-24 | Abbvie Inc | Proteinas de union a il-17 |
| MX2011010158A (es) * | 2009-04-07 | 2011-10-17 | Roche Glycart Ag | Anticuerpos biespecificos anti-erbb-2/anti-c-met. |
| CN102459346B (zh) * | 2009-04-27 | 2016-10-26 | 昂考梅德药品有限公司 | 制造异源多聚体分子的方法 |
| AU2010242830C1 (en) * | 2009-05-01 | 2014-02-13 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| TW201109438A (en) * | 2009-07-29 | 2011-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| PE20121647A1 (es) | 2009-08-29 | 2012-12-31 | Abbvie Inc | Proteinas terapeuticas de union a dll4 |
| TW201119673A (en) * | 2009-09-01 | 2011-06-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| US20110172398A1 (en) * | 2009-10-02 | 2011-07-14 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules for anti-angiogenesis therapy |
| UY32948A (es) | 2009-10-15 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| EP3485908B1 (en) | 2009-10-16 | 2021-08-18 | Mereo BioPharma 5, Inc. | Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents |
| UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| SG10201501562VA (en) | 2010-03-02 | 2015-04-29 | Abbvie Inc | Therapeutic dll4 binding proteins |
| US20130089560A1 (en) * | 2010-03-17 | 2013-04-11 | Oncomed Pharmaceuticals Inc | Bone morphogenetic protein receptor binding agents and methods of their use |
| TWI426920B (zh) * | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體 |
| BR112012025568A2 (pt) | 2010-04-07 | 2017-03-28 | Abbvie Inc | proteínas de ligação ao tnf-<244>. |
| CA2804399A1 (en) | 2010-07-06 | 2012-01-12 | Aveo Pharmaceuticals, Inc. | Anti-ron antibodies |
| TW201206473A (en) | 2010-08-03 | 2012-02-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| CN103260639A (zh) | 2010-08-26 | 2013-08-21 | Abbvie公司 | 双重可变结构域免疫球蛋白及其用途 |
| EP3264089A1 (en) | 2010-08-31 | 2018-01-03 | Genentech, Inc. | Biomarkers and methods of treatment |
| TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
| US8551479B2 (en) | 2010-09-10 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
| US8962804B2 (en) | 2010-10-08 | 2015-02-24 | City Of Hope | Meditopes and meditope-binding antibodies and uses thereof |
| EP2624868B1 (en) | 2010-10-08 | 2018-09-26 | City of Hope | A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use |
| TWI636993B (zh) | 2010-10-27 | 2018-10-01 | 安美基公司 | Ｄｋｋ１抗體及使用方法 |
| MX2013004979A (es) * | 2010-11-02 | 2013-07-30 | Abbott Lab | Inmunoglobulinas de dominio variable doble y usos de las mismas. |
| CN103459422A (zh) * | 2010-11-24 | 2013-12-18 | 葛兰素集团有限公司 | 靶向hgf的多特异性抗原结合蛋白 |
| LT2647707T (lt) | 2010-11-30 | 2018-11-12 | Chugai Seiyaku Kabushiki Kaisha | Citotoksiškumą indukuojantis terapinis agentas |
| WO2012088290A2 (en) * | 2010-12-22 | 2012-06-28 | Abbott Laboratories | Tri-variable domain binding proteins and uses thereof |
| MX2013008736A (es) * | 2011-01-28 | 2013-11-22 | Ca Nat Research Council | Diseño de dominios de inmunoglobulina. |
| JP2014509588A (ja) | 2011-03-01 | 2014-04-21 | アムジエン・インコーポレーテツド | 二特異性結合剤 |
| US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| WO2012138880A2 (en) * | 2011-04-07 | 2012-10-11 | The Brigham And Women's Hospital, Inc. | Methods of treating inflammatory diseases by targeting the chemoattractant cytokine receptor 2 (ccr2) or chemokine (c-c motif) ligand 2 (ccl2) |
| GB201116092D0 (en) | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
| KR20140064971A (ko) | 2011-09-19 | 2014-05-28 | 제넨테크, 인크. | c-met 길항제 및 B-raf 길항제를 포함하는 조합 치료 |
| HRP20190044T1 (hr) * | 2011-09-23 | 2019-02-22 | Oncomed Pharmaceuticals, Inc. | Agensi koji vežu vegf/dll4 i njihove uporabe |
| WO2013055404A1 (en) * | 2011-10-10 | 2013-04-18 | City Of Hope | Meditopes and meditope-binding antibodies and uses thereof |
| US9127056B2 (en) | 2011-10-17 | 2015-09-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monospecific and bispecific human monoclonal antibodies targeting insulin-like growth factor II (IGF-II) |
| US11851476B2 (en) | 2011-10-31 | 2023-12-26 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain |
| AU2012340826A1 (en) | 2011-11-21 | 2014-05-29 | Genentech, Inc. | Purification of anti-c-met antibodies |
| AU2012362370A1 (en) * | 2011-12-30 | 2014-07-24 | Abbvie Inc. | Dual variable domain immunoglobulins against receptors |
| WO2013102042A2 (en) | 2011-12-30 | 2013-07-04 | Abbvie Inc. | Dual specific binding proteins directed against il-13 and/or il-17 |
| US9428553B2 (en) | 2012-02-10 | 2016-08-30 | City Of Hope | Meditopes and meditope-binding antibodies and uses thereof |
| JP6850528B2 (ja) | 2012-02-13 | 2021-03-31 | シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート | 二重特異性キメラ抗原受容体およびその治療的使用 |
| ES2741936T3 (es) | 2012-02-24 | 2020-02-12 | Abbvie Stemcentrx Llc | Anticuerpos anti-SEZ6 y procedimientos de uso |
| US9090694B2 (en) | 2012-04-30 | 2015-07-28 | Janssen Biotech, Inc. | ST2L antibody antagonists |
| US20140004131A1 (en) | 2012-05-04 | 2014-01-02 | Novartis Ag | Antibody formulation |
| SG11201408538PA (en) | 2012-07-13 | 2015-02-27 | Roche Glycart Ag | Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases |
| PL3489261T3 (pl) | 2012-08-24 | 2021-08-16 | The Regents Of The University Of California | Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu |
| EP2893343B1 (en) | 2012-09-07 | 2019-11-20 | The Governors of the University of Alberta | Methods for diagnosis of inflammatory liver disease |
| AU2013337811A1 (en) | 2012-10-31 | 2015-05-14 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a DLL4 antagonist |
| HK1212359A1 (en) * | 2012-11-01 | 2016-06-10 | Abbvie Inc. | Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof |
| BR112015009924A2 (pt) * | 2012-11-01 | 2017-12-05 | Abbvie Inc | formulações de proteína imunoglobulina de domínio variável duplo estáveis |
| US20140154255A1 (en) * | 2012-11-30 | 2014-06-05 | Abbvie Biotherapeutics Inc. | Anti-vegf antibodies and their uses |
| CA2890455A1 (en) | 2012-12-04 | 2014-06-12 | Abbvie, Inc. | Blood-brain barrier (bbb) penetrating dual specific binding proteins |
| JP2016504337A (ja) * | 2012-12-20 | 2016-02-12 | メディミューン，エルエルシー | イオン交換クロマトグラフィーを使用して高マンノースグリコフォームのレベルを制御する方法 |
| EP2948475A2 (en) | 2013-01-23 | 2015-12-02 | AbbVie Inc. | Methods and compositions for modulating an immune response |
| US9989524B2 (en) | 2013-02-05 | 2018-06-05 | Sanofi | Immuno imaging agent for use with antibody-drug conjugate therapy |
| US9844607B2 (en) * | 2013-02-05 | 2017-12-19 | Sanofi | Immuno imaging agent for use with antibody-drug conjugate therapy |
| CN104994879A (zh) | 2013-02-22 | 2015-10-21 | 霍夫曼-拉罗奇有限公司 | 治疗癌症和预防药物抗性的方法 |
| CN105358575B (zh) | 2013-03-15 | 2020-09-22 | 詹森生物科技公司 | 干扰素α和ω抗体拮抗剂 |
| JP2016522793A (ja) | 2013-03-15 | 2016-08-04 | アッヴィ・インコーポレイテッド | ＩＬ−１βおよび／またはＩＬ−１７に対して指向された二重特異的結合タンパク質 |
| KR20160006168A (ko) | 2013-03-18 | 2016-01-18 | 바이오서오엑스 프로덕스 비.브이. | 인간화 항-cd134(ox40) 항체 및 이의 용도 |
| KR102049990B1 (ko) * | 2013-03-28 | 2019-12-03 | 삼성전자주식회사 | c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질 |
| RU2652880C2 (ru) * | 2013-04-07 | 2018-05-03 | Дженрикс (Шанхай) Байофармасертикал Ко., Лтд. | Антитело против рецептора эпидермального фактора роста |
| CN105518028B (zh) * | 2013-07-09 | 2019-08-13 | Abl生物公司 | 与dll4和vegf特异性结合的新型双靶向蛋白及其用途 |
| KR102236367B1 (ko) * | 2013-07-26 | 2021-04-05 | 삼성전자주식회사 | DARPin을 포함하는 이중 특이 키메라 단백질 |
| EP3757130A1 (en) | 2013-09-26 | 2020-12-30 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| LT3065774T (lt) | 2013-11-06 | 2021-09-10 | Janssen Biotech, Inc. | Anti-ccl17 antikūnai |
| MX376384B (es) | 2013-11-27 | 2025-03-07 | Zymeworks Bc Inc | Construcciones de union a antigenos biespecificas dirigidas a her2. |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| PL3104853T3 (pl) | 2014-02-10 | 2020-05-18 | Respivant Sciences Gmbh | Leczenie stabilizatorami komórek tucznych zaburzeń ogólnoustrojowych |
| CA2938996A1 (en) | 2014-02-10 | 2015-08-13 | Patara Pharma, LLC | Methods for the treatment of lung diseases with mast cell stabilizers |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| ME03558B (me) | 2014-03-14 | 2020-07-20 | Novartis Ag | Molekuli anti-lag-3 antiтela i njihove upotrebe |
| EP3122900A1 (en) | 2014-03-24 | 2017-02-01 | F. Hoffmann-La Roche AG | Cancer treatment with c-met antagonists and correlation of the latter with hgf expression |
| MX380176B (es) | 2014-04-07 | 2025-03-12 | Chugai Pharmaceutical Co Ltd | Molecula ligada a antigeno inmunoactivada. |
| EP2930188A1 (en) * | 2014-04-13 | 2015-10-14 | Affimed Therapeutics AG | Trifunctional antigen-binding molecule |
| KR102223502B1 (ko) | 2014-05-09 | 2021-03-05 | 삼성전자주식회사 | 항 c-Met/항 EGFR/항 Her3 다중 특이 항체 및 이의 이용 |
| US11505605B2 (en) | 2014-05-13 | 2022-11-22 | Chugai Seiyaku Kabushiki Kaisha | T cell-redirected antigen-binding molecule for cells having immunosuppression function |
| JP2017524371A (ja) | 2014-05-23 | 2017-08-31 | ジェネンテック， インコーポレイテッド | Ｍｉｔバイオマーカーとその使用方法 |
| TWI713453B (zh) | 2014-06-23 | 2020-12-21 | 美商健生生物科技公司 | 干擾素α及ω抗體拮抗劑 |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| US9884921B2 (en) | 2014-07-01 | 2018-02-06 | Pfizer Inc. | Bispecific heterodimeric diabodies and uses thereof |
| MY192918A (en) | 2014-09-09 | 2022-09-15 | Janssen Biotech Inc | Combination therapies with anti-cd38 antibodies |
| KR20170060042A (ko) | 2014-09-13 | 2017-05-31 | 노파르티스 아게 | Alk 억제제의 조합 요법 |
| US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
| MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| MX382902B (es) | 2014-10-31 | 2025-03-13 | Oncomed Pharm Inc | Inhibidor de la vía noth en combinación con un agente inmunoterapéutico para usarse en el tratamiento de cáncer. |
| KR102309881B1 (ko) | 2014-11-21 | 2021-10-06 | 삼성전자주식회사 | c-Met 및 EGFR의 이중 저해제 및 IGF-1R 저해제를 포함하는 병용 투여용 약학 조성물 |
| CA2968258A1 (en) | 2014-11-27 | 2016-06-02 | Zymeworks Inc. | Methods of using bispecific antigen-binding constructs targeting her2 |
| EP3227338A4 (en) | 2014-12-04 | 2018-05-16 | Janssen Biotech, Inc. | Anti-cd38 antibodies for treatment of acute myeloid leukemia |
| ES2764299T3 (es) | 2014-12-09 | 2020-06-02 | Inst Nat Sante Rech Med | Anticuerpos monoclonales humanos contra AXL |
| AU2015360609A1 (en) | 2014-12-09 | 2017-06-29 | Abbvie Inc. | Antibody drug conjugates with cell permeable Bcl-xL inhibitors |
| WO2016094881A2 (en) | 2014-12-11 | 2016-06-16 | Abbvie Inc. | Lrp-8 binding proteins |
| WO2016135041A1 (en) | 2015-02-26 | 2016-09-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fusion proteins and antibodies comprising thereof for promoting apoptosis |
| WO2016168769A1 (en) * | 2015-04-15 | 2016-10-20 | The California Institute For Biomedical Research | Chimeric receptor t cell switches for her2 |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| CR20170526A (es) | 2015-05-20 | 2018-04-03 | Janssen Biotech Inc | ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38 |
| TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白 |
| MY192978A (en) | 2015-06-22 | 2022-09-20 | Janssen Biotech Inc | Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors |
| HUE066300T2 (hu) | 2015-06-24 | 2024-07-28 | Janssen Biotech Inc | Immunmoduláció és szolid tumorok kezelése CD38-hoz specifikusan kötõdõ antitestekkel |
| CA2994825A1 (en) | 2015-08-05 | 2017-02-09 | Janssen Biotech, Inc. | Anti-cd154 antibodies and methods of using them |
| EP3331522A1 (en) | 2015-08-07 | 2018-06-13 | Patara Pharma LLC | Methods for the treatment of mast cell related disorders with mast cell stabilizers |
| US10265296B2 (en) | 2015-08-07 | 2019-04-23 | Respivant Sciences Gmbh | Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders |
| US11197934B2 (en) * | 2015-09-17 | 2021-12-14 | The Scripps Research Institute | Dual variable domain immunoconjugates and uses thereof |
| WO2017053705A1 (en) | 2015-09-23 | 2017-03-30 | Oncomed Pharmaceuticals, Inc. | Methods and compositions for treatment of cancer |
| PL3827845T3 (pl) | 2015-11-03 | 2022-07-11 | Janssen Biotech, Inc. | Formulacje podskórne przeciwciał anty-cd38 i ich zastosowania |
| JP6931329B2 (ja) | 2015-11-18 | 2021-09-01 | 中外製薬株式会社 | 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法 |
| EP3378488A4 (en) | 2015-11-18 | 2019-10-30 | Chugai Seiyaku Kabushiki Kaisha | METHOD FOR IMPROVING THE HUMORAL IMMUNE REACTION |
| EP3390453A2 (en) | 2015-12-17 | 2018-10-24 | Janssen Biotech, Inc. | Antibodies specifically binding hla-dr and their uses |
| JP7219005B2 (ja) | 2015-12-28 | 2023-02-07 | 中外製薬株式会社 | Ｆｃ領域含有ポリペプチドの精製を効率化するための方法 |
| WO2017117464A1 (en) | 2015-12-30 | 2017-07-06 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| WO2017125897A1 (en) | 2016-01-21 | 2017-07-27 | Novartis Ag | Multispecific molecules targeting cll-1 |
| AU2017214692B2 (en) * | 2016-02-06 | 2021-11-04 | Epimab Biotherapeutics, Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
| KR102456433B1 (ko) | 2016-03-02 | 2022-10-19 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 에리불린-기반 항체-약물 콘주게이트 및 사용 방법 |
| EP3431102A4 (en) | 2016-03-14 | 2019-09-25 | Chugai Seiyaku Kabushiki Kaisha | CELL DAMAGING THERAPEUTIC MEDICAMENT FOR USE IN CANCER THERAPY |
| PL3458479T4 (pl) | 2016-06-08 | 2021-07-26 | Abbvie Inc. | Przeciwciała anty-b7-h3 i koniugaty przeciwciało-lek |
| CA3029003A1 (en) | 2016-06-27 | 2018-01-04 | The Regents Of The University Of California | Cancer treatment combinations |
| JP2019527678A (ja) | 2016-06-28 | 2019-10-03 | ユーエムセー・ユトレヒト・ホールディング・ベー・フェー | ＣＤ３８に特異的に結合する抗体によるＩｇＥ媒介疾患の治療 |
| CN106977602B (zh) | 2016-08-23 | 2018-09-25 | 中山康方生物医药有限公司 | 一种抗pd1单克隆抗体、其药物组合物及其用途 |
| CN106967172B (zh) | 2016-08-23 | 2019-01-08 | 康方药业有限公司 | 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途 |
| WO2018035710A1 (en) | 2016-08-23 | 2018-03-01 | Akeso Biopharma, Inc. | Anti-ctla4 antibodies |
| AU2017321495A1 (en) | 2016-08-31 | 2019-03-21 | Respivant Sciences Gmbh | Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis |
| AU2017339366A1 (en) | 2016-10-07 | 2019-04-11 | Respivant Sciences Gmbh | Cromolyn compositions for treatment of pulmonary fibrosis |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| EP3737949A1 (en) | 2018-01-12 | 2020-11-18 | Genzyme Corporation | Methods for the quantitation of polypeptides |
| BR112020017872A2 (pt) | 2018-03-02 | 2020-12-22 | Kodiak Sciences Inc. | Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos |
| EP3774880A1 (en) | 2018-03-29 | 2021-02-17 | AbbVie Inc. | Selective reduction of antibodies |
| JP7368453B2 (ja) | 2018-05-03 | 2023-10-24 | シャンハイ エピムアブ バイオセラピューティクス カンパニー リミテッド | Ｐｄ－１およびｌａｇ－３に対する高親和性抗体ならびにそれらから作製された二重特異性結合タンパク質 |
| AU2019270624B2 (en) | 2018-05-16 | 2024-05-02 | Janssen Biotech, Inc. | Methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| KR102503349B1 (ko) | 2019-05-14 | 2023-02-23 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| CN110297085A (zh) * | 2019-06-13 | 2019-10-01 | 武汉博士德生物工程有限公司 | 一种用于增强免疫印迹检测信号的抗体稀释液 |
| US12077585B2 (en) | 2019-07-26 | 2024-09-03 | Janssen Biotech, Inc. | Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses |
| PH12022550348A1 (en) | 2019-08-15 | 2022-12-12 | Janssen Biotech Inc | Materials and methods for improved single chain variable fragments |
| WO2021072265A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| IL295129A (en) | 2020-01-30 | 2022-09-01 | Umoja Biopharma Inc | Bispecific transduction enhancer |
| TW202144389A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在多發性骨髓瘤中表現之新抗原及其用途 |
| TW202144388A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在卵巢癌中表現之新抗原及其用途 |
| UY40280A (es) | 2020-03-13 | 2023-07-31 | Janssen Biotech Inc | Dominios de unión a antígeno que se unen a la proteina cd33 de la superficie de células mieloides |
| KR20230017841A (ko) | 2020-05-27 | 2023-02-06 | 얀센 바이오테크 인코포레이티드 | Cd3 항원 결합 도메인을 포함하는 단백질 및 이의 용도 |
| US12006366B2 (en) | 2020-06-11 | 2024-06-11 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| EP4175664A2 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| TW202221028A (zh) | 2020-07-29 | 2022-06-01 | 美商健生生物科技公司 | 包括hla-g抗原結合域之蛋白及其用途 |
| TW202233672A (zh) | 2020-10-22 | 2022-09-01 | 美商健生生物科技公司 | 包括類δ配體３（ＤＬＬ３）抗原結合區之蛋白質及其用途 |
| AR124681A1 (es) | 2021-01-20 | 2023-04-26 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
| CA3214307A1 (en) | 2021-03-24 | 2022-09-29 | Janssen Biotech, Inc. | Proteins comprising cd3 antigen binding domains and uses thereof |
| CN117098781A (zh) | 2021-03-24 | 2023-11-21 | 詹森生物科技公司 | 靶向cd22和cd79b的抗体 |
| AU2022344595A1 (en) | 2021-09-13 | 2024-05-02 | Janssen Biotech, Inc | CD33 X Vδ2 MULTISPECIFIC ANTIBODIES FOR THE TREATMENT OF CANCER |
| US20250019455A1 (en) | 2021-09-24 | 2025-01-16 | Pharmaceutica Nv | Proteins comprising cd20 binding domains, and uses thereof |
| AU2022380722A1 (en) | 2021-11-03 | 2024-06-20 | Janssen Biotech, Inc. | Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies |
| CA3239224A1 (en) | 2021-11-22 | 2023-05-25 | Janssen Biotech, Inc. | Compositions comprising enhanced multispecific binding agents for an immune response |
| KR20240154641A (ko) * | 2022-03-02 | 2024-10-25 | 바이오뮤넥스 파마슈티컬스 | Her-3, 및 her-2 또는 egfr에 결합하는 이중특이적 항체 |
| EP4608874A2 (en) * | 2022-10-28 | 2025-09-03 | Memorial Sloan Kettering Cancer Center | Anti-adam10 antibodies and uses in treatment of cancer |
| AU2023375177A1 (en) | 2022-11-02 | 2025-06-19 | Janssen Biotech, Inc. | Methods of treating cancers |
| WO2025034715A1 (en) | 2023-08-07 | 2025-02-13 | Janssen Biotech, Inc. | Gucy2c antibodies and uses thereof |
| WO2025231408A2 (en) | 2024-05-03 | 2025-11-06 | Janssen Biotech, Inc. | Methods for treating multiple myeloma with car-t cells and bispecific antibodies |
| WO2025231372A2 (en) | 2024-05-03 | 2025-11-06 | Janssen Biotech, Inc. | Methods for treating multiple myeloma with car-t cells and bispecific antibodies |
Family Cites Families (391)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2128208A (en) | 1937-02-27 | 1938-08-23 | Du Pont | Alkoxy derivatives of methacrylic acid esters and method of producing them |
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| ATE37983T1 (de) | 1982-04-22 | 1988-11-15 | Ici Plc | Mittel mit verzoegerter freigabe. |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4753894A (en) | 1984-02-08 | 1988-06-28 | Cetus Corporation | Monoclonal anti-human breast cancer antibodies |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| US5128326A (en) | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
| WO1986005803A1 (fr) | 1985-03-30 | 1986-10-09 | Marc Ballivet | Procede d'obtention d'adn, arn, peptides, polypeptides ou proteines, par une technique de recombinaison d'adn |
| US6492107B1 (en) | 1986-11-20 | 2002-12-10 | Stuart Kauffman | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| DE3600905A1 (de) | 1986-01-15 | 1987-07-16 | Ant Nachrichtentech | Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen |
| US4699784A (en) | 1986-02-25 | 1987-10-13 | Center For Molecular Medicine & Immunology | Tumoricidal methotrexate-antibody conjugate |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| EP0273115B1 (en) | 1986-10-22 | 1994-09-07 | Abbott Laboratories | Chemiluminescent acridinium and phenanthridinium salts |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US4880078A (en) | 1987-06-29 | 1989-11-14 | Honda Giken Kogyo Kabushiki Kaisha | Exhaust muffler |
| JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク，インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
| US5006309A (en) | 1988-04-22 | 1991-04-09 | Abbott Laboratories | Immunoassay device with liquid transfer between wells by washing |
| US5089424A (en) | 1988-06-14 | 1992-02-18 | Abbott Laboratories | Method and apparatus for heterogeneous chemiluminescence assay |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| EP1997891A1 (en) | 1988-09-02 | 2008-12-03 | Dyax Corporation | Generation and selection of recombinant varied binding proteins |
| US5241070A (en) | 1988-09-26 | 1993-08-31 | Ciba Corning Diagnostics Corp. | Nucleophilic polysubstituted aryl acridinium esters and uses thereof |
| WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
| SE462454B (sv) | 1988-11-10 | 1990-06-25 | Pharmacia Ab | Maetyta foer anvaendning i biosensorer |
| WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| US5063081A (en) | 1988-11-14 | 1991-11-05 | I-Stat Corporation | Method of manufacturing a plurality of uniform microfabricated sensing devices having an immobilized ligand receptor |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| FI915411A7 (fi) | 1989-05-16 | 1991-11-15 | Scripps Research Inst | Heteromeeristen reseptorien koe-ekspressio |
| CA2016841C (en) | 1989-05-16 | 1999-09-21 | William D. Huse | A method for producing polymers having a preselected activity |
| CA2016842A1 (en) | 1989-05-16 | 1990-11-16 | Richard A. Lerner | Method for tapping the immunological repertoire |
| WO1991005548A1 (en) | 1989-10-10 | 1991-05-02 | Pitman-Moore, Inc. | Sustained release composition for macromolecular proteins |
| AU642932B2 (en) | 1989-11-06 | 1993-11-04 | Alkermes Controlled Therapeutics, Inc. | Protein microspheres and methods of using them |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| AT396939B (de) | 1990-05-29 | 1993-12-27 | Alois Dipl Ing Dr Jungbauer | Komplexes virales antigen von hiv-1 bindendes rekombinantes protein |
| AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| WO1992002551A1 (en) | 1990-08-02 | 1992-02-20 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
| US5135875A (en) | 1990-08-15 | 1992-08-04 | Abbott Laboratories | Protein precipitation reagent |
| CA2048302A1 (en) | 1990-08-15 | 1992-02-16 | Victoria P. Meucci | Solubilization reagent for biological test samples |
| EP0544809B1 (en) | 1990-08-24 | 1998-12-16 | Ixsys, Inc. | Methods of synthesizing oligonucleotides with random codons |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| US5780279A (en) | 1990-12-03 | 1998-07-14 | Genentech, Inc. | Method of selection of proteolytic cleavage sites by directed evolution and phagemid display |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| CA2098824A1 (en) | 1990-12-20 | 1992-06-21 | William D. Huse | Optimization of binding proteins |
| ATE439435T1 (de) | 1991-03-01 | 2009-08-15 | Dyax Corp | Chimäres protein mit mikroprotein mit zwei oder mehr disulfidbindungen und ausgestaltungen davon |
| DK0531472T3 (da) | 1991-03-06 | 2003-12-01 | Merck Patent Gmbh | Humaniserede monoklonale antistoffer |
| DE69233701T2 (de) | 1991-03-18 | 2008-04-10 | New York University | Monoklonale und chimäre Antikörper spezifisch für menschlichen Tumornekrosefaktor |
| US6277969B1 (en) * | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| DE69233750D1 (de) | 1991-04-10 | 2009-01-02 | Scripps Research Inst | Bibliotheken heterodimerer Rezeptoren mittels Phagemiden |
| US5795965A (en) * | 1991-04-25 | 1998-08-18 | Chugai Seiyaku Kabushiki Kaisha | Reshaped human to human interleukin-6 receptor |
| JPH06507404A (ja) | 1991-05-01 | 1994-08-25 | ヘンリー エム．ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン | 感染性の呼吸性疾患の治療方法 |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| DE4118120A1 (de) | 1991-06-03 | 1992-12-10 | Behringwerke Ag | Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung |
| CA2069530A1 (en) | 1991-06-03 | 1992-12-04 | Cass J. Grandone | Reagent pack for immunoassays |
| WO1992022324A1 (en) | 1991-06-14 | 1992-12-23 | Xoma Corporation | Microbially-produced antibody fragments and their conjugates |
| EP0590058B1 (en) * | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| JP3540315B2 (ja) | 1991-09-23 | 2004-07-07 | メディカル リサーチ カウンシル | キメラ抗体の製造−組合せアプローチ |
| AU3178993A (en) | 1991-11-25 | 1993-06-28 | Enzon, Inc. | Multivalent antigen-binding proteins |
| ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| DE69233204T2 (de) | 1991-12-13 | 2004-07-15 | Xoma Corp., Berkeley | Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| WO1993020442A1 (en) | 1992-03-30 | 1993-10-14 | Abbott Laboratories | Reagents and methods for the detection and quantification of thyroxine in fluid samples |
| US5352803A (en) | 1992-03-30 | 1994-10-04 | Abbott Laboratories | 5(6)-methyl substituted fluorescein derivatives |
| WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| ES2091684T3 (es) | 1992-11-13 | 1996-11-01 | Idec Pharma Corp | Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b. |
| US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
| WO1994018219A1 (en) | 1993-02-02 | 1994-08-18 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
| US6491916B1 (en) | 1994-06-01 | 2002-12-10 | Tolerance Therapeutics, Inc. | Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies |
| WO1995001997A1 (en) | 1993-07-09 | 1995-01-19 | Smithkline Beecham Corporation | RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN |
| WO1995009917A1 (en) | 1993-10-07 | 1995-04-13 | The Regents Of The University Of California | Genetically engineered bispecific tetravalent antibodies |
| EP0659766A1 (en) | 1993-11-23 | 1995-06-28 | Schering-Plough | Human monoclonal antibodies against human cytokines and methods of making and using such antibodies |
| US5565352A (en) | 1993-11-24 | 1996-10-15 | Arch Development Corporation | Deubiquitinating enzyme: compositions and methods |
| WO1995015982A2 (en) | 1993-12-08 | 1995-06-15 | Genzyme Corporation | Process for generating specific antibodies |
| GB9401182D0 (en) | 1994-01-21 | 1994-03-16 | Inst Of Cancer The Research | Antibodies to EGF receptor and their antitumour effect |
| DK1231268T3 (da) | 1994-01-31 | 2005-11-21 | Univ Boston | Polyklonale antistofbiblioteker |
| ZA95960B (en) | 1994-03-14 | 1995-10-10 | Genetics Inst | Use of interleukin-12 antagonists in the treatment of autoimmune diseases |
| HU221001B1 (hu) | 1994-03-17 | 2002-07-29 | Merck Patent Gmbh. | Egyláncú anti-EGFR Fv-k és anti-EGFR ellenanyagok |
| IL109632A (en) | 1994-05-11 | 2007-03-08 | Yeda Res & Dev | Modulators of the function of tnf receptors |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| ATE306930T1 (de) * | 1994-08-12 | 2005-11-15 | Immunomedics Inc | Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper |
| EP0805678B1 (en) | 1995-01-05 | 2003-10-29 | THE BOARD OF REGENTS acting for and on behalf of THE UNIVERSITY OF MICHIGAN | Surface-modified nanoparticles and method of making and using same |
| GB9504344D0 (en) * | 1995-03-03 | 1995-04-19 | Unilever Plc | Antibody fragment production |
| US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| US6091001A (en) | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| JPH11503914A (ja) | 1995-04-21 | 1999-04-06 | セル ジェネシス，インコーポレイテッド | 大ゲノムｄｎａ欠失の生成 |
| JP4312259B2 (ja) | 1995-04-27 | 2009-08-12 | アムジェン フレモント インク． | 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US7060808B1 (en) * | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
| AU6267896A (en) | 1995-06-07 | 1996-12-30 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth oftumors |
| AU710347B2 (en) | 1995-08-31 | 1999-09-16 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of an agent |
| BR9606706A (pt) * | 1995-10-16 | 1999-04-06 | Unilever Nv | Análogo de fragmento de anticorpo biespecífico ou bivalente uso processo para produzir o mesmo |
| US6090382A (en) * | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| US6331431B1 (en) | 1995-11-28 | 2001-12-18 | Ixsys, Inc. | Vacuum device and method for isolating periplasmic fraction from cells |
| JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
| DE69721548T2 (de) | 1996-02-09 | 2004-04-01 | Abbott Laboratories(Bermuda)Ltd. | HUMANE ANTIKÖRPER WELCHE AN HUMANEN TNFalpha BINDEN |
| ATE508733T1 (de) | 1996-03-04 | 2011-05-15 | Penn State Res Found | Materialien und verfahren zur steigerung der zellulären internalisierung |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| JPH11507843A (ja) * | 1996-03-28 | 1999-07-13 | ザ・ジョンズ・ホプキンス・ユニバーシティー | タンパク質の可溶性二価および多価ヘテロ二量体類縁体 |
| ES2225961T3 (es) | 1996-04-04 | 2005-03-16 | Unilever N.V. | Proteina de union a antigeno multivalente y multiespecifica. |
| US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| US6699658B1 (en) | 1996-05-31 | 2004-03-02 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| US6986890B1 (en) * | 1996-11-21 | 2006-01-17 | Kyowa Hakko Kogyo Co., Ltd. | Anti-human VEGF receptor Flt-1 monoclonal antibody |
| US7258857B2 (en) * | 1996-11-22 | 2007-08-21 | The Trustees Of Columbia University In The City Of New York | Rage-related methods for treating inflammation |
| DE69738539T2 (de) | 1996-12-03 | 2009-03-26 | Amgen Fremont Inc. | Vollkommen humane Antikörper die EGFR binden |
| WO1998031346A1 (en) | 1997-01-16 | 1998-07-23 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| PT971946E (pt) | 1997-01-21 | 2006-11-30 | Gen Hospital Corp | Selecção de proteínas utilizando fusões arn-proteína |
| US7306914B2 (en) | 1997-01-31 | 2007-12-11 | Odyssey Thera Inc. | Protein fragment complementation assays in whole animals applications to drug efficacy, ADME, cancer biology, immunology, infectious disease and gene therapy |
| US6057098A (en) | 1997-04-04 | 2000-05-02 | Biosite Diagnostics, Inc. | Polyvalent display libraries |
| US6884879B1 (en) * | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| ES2236634T3 (es) * | 1997-04-07 | 2005-07-16 | Genentech, Inc. | Anticuerpos anti-vegf. |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| NZ516848A (en) | 1997-06-20 | 2004-03-26 | Ciphergen Biosystems Inc | Retentate chromatography apparatus with applications in biology and medicine |
| EP1007967A2 (en) | 1997-08-04 | 2000-06-14 | Ixsys, Incorporated | Methods for identifying ligand specific binding molecules |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| SE512663C2 (sv) | 1997-10-23 | 2000-04-17 | Biogram Ab | Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer |
| BR9813276A (pt) | 1997-10-27 | 2000-08-22 | Unilever Nv | Proteìna multivalente de ligação de antìgeno, sequências de nucleotìdeos, vetor de expressão, célula hospedeira, processo para preparação de proteìna multivalente de ligação de antìgeno, e, uso da mesma |
| US7179892B2 (en) * | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
| JP2002505097A (ja) | 1998-03-03 | 2002-02-19 | アブジェニックス インク． | 治療薬としてのｃｄ１４７結合分子 |
| CA2323638A1 (en) | 1998-04-03 | 1999-10-14 | Phylos, Inc. | Addressable protein arrays |
| US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| ATE321066T1 (de) | 1998-05-06 | 2006-04-15 | Genentech Inc | Anti-her2 antikörperzusammensetzung |
| CA2336139C (en) | 1998-06-24 | 2008-10-14 | Advanced Inhalation Research, Inc. | Large porous particles emitted from an inhaler |
| US6406921B1 (en) | 1998-07-14 | 2002-06-18 | Zyomyx, Incorporated | Protein arrays for high-throughput screening |
| CA2341029A1 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| US20030215458A1 (en) | 1998-09-30 | 2003-11-20 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| WO2000034337A1 (en) | 1998-12-10 | 2000-06-15 | Tsukuba Research Laboratory, Toagosei Co., Ltd. | Humanized monoclonal antibodies against vascular endothelial cell growth factor |
| WO2000037504A2 (en) | 1998-12-23 | 2000-06-29 | Pfizer Inc. | Human monoclonal antibodies to ctla-4 |
| US8003772B2 (en) | 1999-01-14 | 2011-08-23 | Martek Biosciences Corporation | Chimeric PUFA polyketide synthase systems and uses thereof |
| BR0008758A (pt) * | 1999-01-15 | 2001-12-04 | Genentech Inc | Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante |
| AU4025300A (en) | 1999-03-24 | 2000-10-09 | Packard Bioscience Company | Continuous porous matrix arrays |
| AU3921600A (en) | 1999-03-25 | 2000-10-09 | Abbott Gmbh & Co. Kg | Human antibodies that bind human il-12 and methods for producing |
| US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
| CA2369292C (en) | 1999-04-09 | 2010-09-21 | Kyowa Hakko Kogyo Co. Ltd. | Method of modulating the activity of functional immune molecules |
| CN1119415C (zh) | 1999-06-04 | 2003-08-27 | 长春迈灵生物工程有限公司 | 抗ca125双功能基因工程抗体的克隆与表达 |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US6531580B1 (en) | 1999-06-24 | 2003-03-11 | Ixsys, Inc. | Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same |
| EP2977063A1 (en) | 1999-06-25 | 2016-01-27 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
| AU1456101A (en) | 1999-11-03 | 2001-05-14 | Maxygen, Inc. | Antibody diversity generation |
| CA2399148A1 (en) | 2000-02-10 | 2001-08-16 | Abbott Laboratories | Antibodies that bind human interleukin-18 and methods of making and using |
| JP2003523407A (ja) | 2000-02-24 | 2003-08-05 | ジェネンテック・インコーポレーテッド | カスパーゼ活性化プロドラック療法 |
| CN1427891A (zh) | 2000-02-25 | 2003-07-02 | 美国政府由(美国)卫生和福利部部长代表 | 具有提高的细胞毒性和产量的抗EGFRvIII的scFv、基于其的免疫毒素、及其应用方法 |
| EP1266014A2 (en) | 2000-03-24 | 2002-12-18 | Peter Kufer | Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| DK1272647T3 (en) | 2000-04-11 | 2014-12-15 | Genentech Inc | Multivalent antibodies and uses thereof |
| AU2001259432B2 (en) | 2000-05-03 | 2005-04-21 | Amgen Inc. | Modified peptides, comprising an FC domain, as therapeutic agents |
| BR0110927A (pt) | 2000-05-19 | 2003-03-11 | Scancell Ltd | Anticorpo, ácido nucléico, vetor, célula, método de fabricar um anticorpo, composição farmacêutica, uso de um anticorpo ou de um ácido nucleico, e, método para o tratamento ou profilaxia do câncer |
| KR100787073B1 (ko) | 2000-06-28 | 2007-12-21 | 글리코파이, 인크. | 변형된 당단백질의 제조방법 |
| US7449308B2 (en) | 2000-06-28 | 2008-11-11 | Glycofi, Inc. | Combinatorial DNA library for producing modified N-glycans in lower eukaryotes |
| EP2386575A3 (en) * | 2000-06-29 | 2011-11-30 | Abbott Laboratories | Dual specificity antibodies and methods of making and using |
| AU2001270609A1 (en) | 2000-06-30 | 2002-01-14 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Heterodimeric fusion proteins |
| US20090081234A1 (en) * | 2000-08-07 | 2009-03-26 | George Heavner | Anti-tnf antibodies, compositions, methods and uses for treatment of depression and related conditions |
| GB0020685D0 (en) | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
| US20030157643A1 (en) | 2000-08-24 | 2003-08-21 | Almond Brian D | Synthetic nucleic acids from aquatic species |
| EP1343820A4 (en) * | 2000-10-13 | 2005-09-14 | Uab Research Foundation | HUMANE SINGLE CHAIN ANTI EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY |
| US7601692B2 (en) | 2000-11-28 | 2009-10-13 | Compugen Ltd. | MCP-1 splice variants and methods of using same |
| US6818392B2 (en) | 2000-12-06 | 2004-11-16 | Abbott Laboratories | Monoclonal antibodies to human immunodeficiency virus and uses thereof |
| KR20030074693A (ko) | 2000-12-28 | 2003-09-19 | 알투스 바이올로직스 인코포레이티드 | 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법 |
| AR032028A1 (es) | 2001-01-05 | 2003-10-22 | Pfizer | Anticuerpos contra el receptor del factor de crecimiento similar a insulina |
| US7667004B2 (en) * | 2001-04-17 | 2010-02-23 | Abmaxis, Inc. | Humanized antibodies against vascular endothelial growth factor |
| US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
| CN1684708A (zh) * | 2001-05-30 | 2005-10-19 | 基因技术股份有限公司 | 抗ngf抗体用于治疗各种疾病 |
| WO2002097048A2 (en) | 2001-05-30 | 2002-12-05 | Centocor, Inc. | ANTI-p40 IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES |
| CZ200438A3 (cs) | 2001-06-13 | 2004-06-16 | Genmab A/S | Název neuveden |
| US20040241745A1 (en) | 2001-07-31 | 2004-12-02 | Tasuku Honjo | Substance specific to pd-1 |
| US20040192898A1 (en) | 2001-08-17 | 2004-09-30 | Jia Audrey Yunhua | Anti-abeta antibodies |
| US7247304B2 (en) * | 2001-08-23 | 2007-07-24 | Genmab A/S | Methods of treating using anti-IL-15 antibodies |
| NZ531818A (en) * | 2001-09-25 | 2005-10-28 | Fujisawa Pharmaceutical Co | Recombinant anti-osteopontin antibody and use in the treatment of autoimmune diseases such as rheumatoid arthritis and osteoarthritis |
| ES2405551T3 (es) | 2001-10-01 | 2013-05-31 | Dyax Corporation | Vectores de presentación eucariotas multicatenarios y usos de los mismos |
| ATE430580T1 (de) | 2001-10-25 | 2009-05-15 | Genentech Inc | Glycoprotein-zusammensetzungen |
| WO2003039486A2 (en) | 2001-11-09 | 2003-05-15 | Idec Pharmaceuticals Corporation | Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies |
| DE10156482A1 (de) | 2001-11-12 | 2003-05-28 | Gundram Jung | Bispezifisches Antikörper-Molekül |
| MXPA04004671A (es) | 2001-11-14 | 2005-08-25 | Johnson & Johnson | Anticuerpos anti-interleucina-6, composiciones, metodos y usos. |
| WO2003062375A2 (en) * | 2001-12-19 | 2003-07-31 | Genentech, Inc. | Stabilizing polypeptides which have been exposed to urea |
| JP4460302B2 (ja) * | 2002-02-05 | 2010-05-12 | ジェネンテック インコーポレイテッド | タンパク質精製法 |
| WO2003068801A2 (en) | 2002-02-11 | 2003-08-21 | Genentech, Inc. | Antibody variants with faster antigen association rates |
| US7317091B2 (en) * | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US7419821B2 (en) | 2002-03-05 | 2008-09-02 | I-Stat Corporation | Apparatus and methods for analyte measurement and immunoassay |
| AU2003226065B2 (en) | 2002-04-12 | 2009-02-26 | Ludwig Institute For Cancer Research, Ltd | Recombinant anti-interleukin-9 antibodies |
| EP1495055B1 (en) | 2002-04-18 | 2013-08-14 | Genencor International, Inc. | Production of functional antibodies in filamentous fungi |
| US20030206898A1 (en) | 2002-04-26 | 2003-11-06 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
| JP4319979B2 (ja) | 2002-04-26 | 2009-08-26 | ジェネンテック・インコーポレーテッド | タンパク質の非アフィニティ精製 |
| AU2003231554A1 (en) | 2002-04-30 | 2003-11-17 | Kyowa Hakko Kogyo Co., Ltd. | Antibody to human insulin-like growth factor |
| US7714189B2 (en) | 2002-05-03 | 2010-05-11 | Monsanto Technology Llc | High tryptophan maize |
| EP2316922B1 (en) | 2002-05-24 | 2013-05-22 | Merck Sharp & Dohme Corp. | Neutralizing human anti-IGFR antibody |
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| SI1523496T1 (sl) | 2002-07-18 | 2011-11-30 | Merus B V | Rekombinantno proizvajanje zmesi protiteles |
| US20040018577A1 (en) | 2002-07-29 | 2004-01-29 | Emerson Campbell John Lewis | Multiple hybrid immunoassay |
| US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| EP1542724A4 (en) * | 2002-08-19 | 2005-10-19 | Abgenix Inc | ANTIBODIES AGAINST THE MONOCYTE 1 CHIMIOATTRACTIVE PROTEIN (MCP-1) AND USES THEREOF |
| AU2003265994B2 (en) | 2002-09-11 | 2010-04-01 | Genentech, Inc. | Protein purification |
| US7820166B2 (en) | 2002-10-11 | 2010-10-26 | Micromet Ag | Potent T cell modulating molecules |
| KR100825547B1 (ko) | 2002-11-22 | 2008-04-25 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 말라리아 기생충에서 ｇｐｉ의 생합성을 억제하는 화합물을스크리닝하는 방법 |
| JP4754219B2 (ja) | 2002-12-02 | 2011-08-24 | アムジエン・フレモント・インコーポレイテツド | 腫瘍壊死因子を対象とする抗体、およびそれらの使用 |
| PT1572744E (pt) * | 2002-12-16 | 2010-09-07 | Genentech Inc | Variantes de imunoglobulina e utilizações destas |
| US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
| CN101014364B (zh) | 2002-12-24 | 2012-01-18 | 里纳特神经系统学公司 | 抗ngf抗体及其使用方法 |
| AU2004205684A1 (en) * | 2003-01-23 | 2004-08-05 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
| JP3803790B2 (ja) | 2003-02-17 | 2006-08-02 | 株式会社東北テクノアーチ | 新規なダイアボディ型二重特異性抗体 |
| CA2517145C (en) | 2003-03-05 | 2017-08-01 | Halozyme, Inc. | Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| US7638605B2 (en) | 2003-05-01 | 2009-12-29 | ImClone, LLC | Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
| US20040234609A1 (en) | 2003-05-14 | 2004-11-25 | Collier Katherine D. | Repeat sequence protein polymer active agent congjugates, methods and uses |
| US20070104722A1 (en) | 2003-05-15 | 2007-05-10 | Iogenetics | Targeted biocides |
| CA2522586C (en) * | 2003-05-31 | 2017-02-21 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders |
| RS53476B (sr) | 2003-07-18 | 2014-12-31 | Amgen Fremont Inc. | Sredstva za specifično vezivanje faktora rasta hepatocita |
| PL3095793T3 (pl) * | 2003-07-28 | 2020-09-07 | Genentech, Inc. | Redukcja wycieku białka A w trakcie chromatografii powinowactwa z białkiem A |
| US20050026881A1 (en) * | 2003-07-31 | 2005-02-03 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease |
| WO2005044853A2 (en) | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anti-vegf antibodies |
| US20050106667A1 (en) * | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| US7662928B2 (en) * | 2003-08-08 | 2010-02-16 | The Research Foundation Of State University Of New York | Anti-FcRn antibodies for treatment of auto/allo immune conditions |
| AU2004280333A1 (en) | 2003-08-22 | 2005-04-21 | Medimmune, Llc | Humanization of antibodies |
| NZ545776A (en) * | 2003-08-22 | 2009-05-31 | Biogen Idec Inc | Improved antibodies having altered effector function and methods for making the same |
| US7723099B2 (en) | 2003-09-10 | 2010-05-25 | Abbott Point Of Care Inc. | Immunoassay device with immuno-reference electrode |
| US7682833B2 (en) | 2003-09-10 | 2010-03-23 | Abbott Point Of Care Inc. | Immunoassay device with improved sample closure |
| US20060134105A1 (en) | 2004-10-21 | 2006-06-22 | Xencor, Inc. | IgG immunoglobulin variants with optimized effector function |
| BRPI0415765A (pt) * | 2003-10-24 | 2006-12-26 | Medtronic Inc | técnicas para tratar desordens neurológicas pela atenuação da produção de mediadores pró-inflamatórios |
| US7968684B2 (en) | 2003-11-12 | 2011-06-28 | Abbott Laboratories | IL-18 binding proteins |
| EP1697543B1 (en) * | 2003-11-21 | 2014-08-20 | ANP Technologies, Inc. | Asymmetrically branched polymer conjugates and microarray assays |
| AU2004297616B2 (en) * | 2003-12-04 | 2008-12-18 | Xencor, Inc. | Methods of generating variant proteins with increased host string content and compositions thereof |
| WO2005056578A2 (en) | 2003-12-09 | 2005-06-23 | Ventria Bioscience | High-level expression of fusion polypeptides in plant seeds utilizing seed-storage proteins as fusion carriers |
| US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
| ITRM20030601A1 (it) | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
| US7297541B2 (en) | 2004-01-26 | 2007-11-20 | Monsanto Technology Llc | Genes encoding 4-hydroxyphenylpyruvate dioxygenase (HPPD) enzymes for plant metabolic engineering |
| US7794713B2 (en) | 2004-04-07 | 2010-09-14 | Lpath, Inc. | Compositions and methods for the treatment and prevention of hyperproliferative diseases |
| EP1755673B1 (en) | 2004-04-12 | 2014-07-23 | MedImmune, LLC | Anti-il-9 antibody formulations and uses thereof |
| AU2005233387B2 (en) | 2004-04-15 | 2011-05-26 | Glycofi, Inc. | Production of galactosylated glycoproteins in lower eukaryotes |
| EP1740616B1 (en) | 2004-04-30 | 2011-12-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-tfr antibody. |
| EP1773881A4 (en) | 2004-05-13 | 2008-08-06 | Imclone Systems Inc | Inhibition of macrophage-stimulating protein receptor (RON) |
| EP1751288A2 (en) | 2004-05-19 | 2007-02-14 | Agrivida, Inc. | Transgenic plants expressing intein modified proteins and associated processes for bio-pharmaceutical production |
| US7150969B2 (en) | 2004-06-04 | 2006-12-19 | Rosetta Inpharmatics Llc | Alternatively spliced isoform of acetyl-CoA carboxylase 2 (ACC2) |
| JP2008512352A (ja) | 2004-07-17 | 2008-04-24 | イムクローン システムズ インコーポレイティド | 新規な四価の二重特異性抗体 |
| ES2414460T3 (es) | 2004-08-04 | 2013-07-19 | Amgen Inc. | Anticuerpos para Dkk-1 |
| US7476724B2 (en) * | 2004-08-05 | 2009-01-13 | Genentech, Inc. | Humanized anti-cmet antibodies |
| GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| WO2006031370A2 (en) | 2004-08-19 | 2006-03-23 | Genentech, Inc. | Polypeptide variants with altered effector function |
| GB0419424D0 (en) | 2004-09-02 | 2004-10-06 | Viragen Scotland Ltd | Transgene optimisation |
| SI1784426T1 (sl) * | 2004-09-03 | 2012-03-30 | Genentech Inc | Humanizirani antagonisti proti beta in njihove uporabe |
| US7910100B2 (en) * | 2004-10-01 | 2011-03-22 | Max-Planck-Gesellschaft zur Forderung der Wissen | Antibodies directed to the mammalian EAG1 ion channel protein |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| WO2006047350A2 (en) * | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
| US20060253100A1 (en) | 2004-10-22 | 2006-11-09 | Medtronic, Inc. | Systems and Methods to Treat Pain Locally |
| WO2006047340A2 (en) * | 2004-10-22 | 2006-05-04 | Amgen Inc. | Methods for refolding of recombinant antibodies |
| US7423128B2 (en) | 2004-11-03 | 2008-09-09 | Amgen Fremont Inc. | Anti-properdin antibodies, and methods for making and using same |
| US20070135620A1 (en) | 2004-11-12 | 2007-06-14 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| WO2006066171A1 (en) | 2004-12-15 | 2006-06-22 | Neuralab Limited | Amyloid βετα antibodies for use in improving cognition |
| HRP20110859T1 (hr) | 2004-12-21 | 2011-12-31 | Medimmune Limited | Protutijela usmjerena na angiopoietin-2 i njihova upotreba |
| US20060162026A1 (en) | 2004-12-23 | 2006-07-20 | Karen Oishi | Expressing TGF-beta proteins in plant plastids |
| EP1851245B1 (en) * | 2005-01-26 | 2012-10-10 | Amgen Fremont Inc. | Antibodies against interleukin-1 beta |
| WO2006089133A2 (en) * | 2005-02-15 | 2006-08-24 | Duke University | Anti-cd19 antibodies and uses in oncology |
| EP1860119B1 (en) * | 2005-02-28 | 2011-08-03 | Institute for Antibodies Co., Ltd. | ANTI-IgSF4 ANTIBODY AND UTILIZATION OF THE SAME |
| CA2645562A1 (en) | 2005-03-11 | 2006-09-21 | Gamelogic Inc. | System and method for rewarding game players |
| ES2565481T3 (es) * | 2005-03-24 | 2016-04-05 | Thrombogenics N.V. | Anticuerpo anti-PlGF novedoso |
| CN101484182B (zh) * | 2005-04-06 | 2014-06-11 | Ibc药品公司 | 由同二聚体、同四聚体或二聚体的二聚体组成的稳定连接复合体的生产方法及用途 |
| EA201100642A1 (ru) | 2005-04-25 | 2011-12-30 | Пфайзер Инк. | Антитела к миостатину |
| US7592429B2 (en) * | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| AU2006244445B2 (en) * | 2005-05-05 | 2013-04-18 | Duke University | Anti-CD19 antibody therapy for autoimmune disease |
| CA2607697C (en) | 2005-05-10 | 2015-01-06 | Biogen Idec Ma Inc. | Treating and evaluating inflammatory disorders |
| WO2006130429A2 (en) | 2005-05-27 | 2006-12-07 | Biogen Idec Ma Inc. | Treatment of cancer |
| EP2460832A3 (en) | 2005-05-27 | 2012-10-31 | Biogen Idec MA Inc. | TWEAK binding antibodies |
| ITRM20050290A1 (it) | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
| CA2612648A1 (en) | 2005-06-24 | 2006-12-28 | Novozymes A/S | Lipases for pharmaceutical use |
| PT1896073E (pt) | 2005-06-30 | 2013-05-28 | Janssen Biotech Inc | Composições, métodos e aplicações de anticorpos anti-il-23 |
| DK1929012T3 (da) | 2005-08-11 | 2011-01-31 | Synthetic Genomics Inc | Fremgangsmåde til in vitro-rekombination |
| US20090215992A1 (en) * | 2005-08-19 | 2009-08-27 | Chengbin Wu | Dual variable domain immunoglobulin and uses thereof |
| TWI323734B (en) * | 2005-08-19 | 2010-04-21 | Abbott Lab | Dual variable domain immunoglobulin and uses thereof |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US20070041905A1 (en) * | 2005-08-19 | 2007-02-22 | Hoffman Rebecca S | Method of treating depression using a TNF-alpha antibody |
| WO2007031875A2 (en) * | 2005-08-26 | 2007-03-22 | Glycart Biotechnology Ag | Modified antigen binding molecules with altered cell signaling activity |
| US7906116B2 (en) * | 2005-09-01 | 2011-03-15 | Parkash Gill | Methods for using and identifying modulators of Delta-like 4 |
| CA2862540C (en) * | 2005-09-21 | 2018-07-31 | The Regents Of The University Of California | Systems, compositions, and methods for local imaging and treatment of pain |
| CA2623517A1 (en) * | 2005-09-23 | 2007-04-05 | Walter Reed Army Institute Of Research (Wrair) | Antibodies with simultaneous subsite specificities to protein and lipid epitopes |
| ES2856451T3 (es) | 2005-10-11 | 2021-09-27 | Amgen Res Munich Gmbh | Composiciones que comprenden anticuerpos específicos para diferentes especies, y usos de las mismas |
| US20080299137A1 (en) | 2005-10-28 | 2008-12-04 | Novo Nordisk A/S | Fusion Proteins That Bind Effector Lymphocytes And Target Cells |
| UA96139C2 (uk) | 2005-11-08 | 2011-10-10 | Дженентек, Інк. | Антитіло до нейропіліну-1 (nrp1) |
| PE20070684A1 (es) | 2005-11-14 | 2007-08-06 | Amgen Inc | MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP |
| WO2007056858A1 (en) | 2005-11-18 | 2007-05-24 | Glenmark Pharmaceuticals S.A. | Anti-alpha2 integrin antibodies and their uses |
| EP1957541A2 (en) | 2005-11-21 | 2008-08-20 | Laboratoires Serono SA | Compositions and methods of producing hybrid antigen binding molecules and uses thereof |
| KR20080090408A (ko) | 2005-11-30 | 2008-10-08 | 아보트 러보러터리즈 | 항-Ａβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법 |
| US7939637B2 (en) * | 2005-12-13 | 2011-05-10 | Medimmune Limited | Insulin-like growth factor antibodies and uses thereof |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| US8377691B2 (en) | 2006-01-26 | 2013-02-19 | Integral Molecular, Inc. | Lipoparticles comprising ion channels, methods of making and using the same |
| JP5068270B2 (ja) | 2006-01-31 | 2012-11-07 | ノバルティス アーゲー | 癌を処置するためのｉｌ−１７アンタゴニスト抗体 |
| US20070207171A1 (en) | 2006-03-01 | 2007-09-06 | Cerus Corporation | Engineered listeria and methods of use thereof |
| US7951918B2 (en) * | 2006-03-17 | 2011-05-31 | Biogen Idec Ma Inc. | Stabilized polypeptide compositions |
| AU2007226863A1 (en) | 2006-03-21 | 2007-09-27 | Wyeth | Methods for preventing and treating amyloidogenic diseases |
| WO2007110205A2 (en) | 2006-03-24 | 2007-10-04 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
| SG170799A1 (en) | 2006-03-28 | 2011-05-30 | Biogen Idec Inc | Anti-igf-ir antibodies and uses thereof |
| US20070232556A1 (en) | 2006-03-31 | 2007-10-04 | Montine Thomas J | Methods and compositions for the treatment of neurological diseases and disorders |
| EP2010213A4 (en) | 2006-04-10 | 2010-08-11 | Abbott Biotech Ltd | USE AND COMPOSITIONS FOR THE TREATMENT OF JUVENIL RHEUMATOID ARTHRITIS |
| CA2648223A1 (en) | 2006-04-14 | 2007-10-25 | Novartis Ag | Use of il-i antibodies for treating ophthalmic disorders |
| WO2007124019A2 (en) | 2006-04-21 | 2007-11-01 | Gtc Biotherapeutics, Inc. | Methods and products related to the transfer of molecules from blood to the mammary gland |
| GEP20125628B (en) | 2006-04-21 | 2012-09-10 | Novartis Ag | Pharmaceutical compositions containing antagonist anti-cd40 antibody |
| US20070254338A1 (en) | 2006-04-24 | 2007-11-01 | Amgen Inc. | Method for making recombinant protein using complementation dependent DHFR mutants |
| US20080118978A1 (en) * | 2006-04-28 | 2008-05-22 | Takashi Sato | Anti-tumor agent |
| CN101058609B (zh) | 2006-05-26 | 2011-04-13 | 神州细胞工程有限公司 | 人源抗体及其表达 |
| AU2007254853B2 (en) * | 2006-06-02 | 2011-11-17 | Aveo Pharmaceuticals, Inc. | Hepatocyte growth factor (HGF) binding proteins |
| CA2654000A1 (en) * | 2006-06-06 | 2008-05-22 | Genentech, Inc. | Anti-dll4 antibodies and methods using same |
| US20080014196A1 (en) * | 2006-06-06 | 2008-01-17 | Genentech, Inc. | Compositions and methods for modulating vascular development |
| CN1884517B (zh) | 2006-06-08 | 2010-06-30 | 武汉禾元生物科技有限公司 | 利用谷物非储藏蛋白为融合载体在胚乳表达多肽的方法及应用 |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| ES2427924T3 (es) * | 2006-06-30 | 2013-11-04 | Merck Sharp & Dohme Corp. | Biomarcador IGFBP2 |
| US20080081379A1 (en) | 2006-07-13 | 2008-04-03 | Sigler Gerald F | Homogeneous double receptor agglutination assay for immunosuppressant drugs |
| TWI551607B (zh) | 2006-07-14 | 2016-10-01 | Ａｃ免疫公司 | 人類化抗體 |
| US7592156B2 (en) | 2006-07-20 | 2009-09-22 | Wyeth | Synthetic dog/human chimeric C-C chemokine receptor 2B |
| US7883855B2 (en) | 2006-07-21 | 2011-02-08 | Abbott Laboratories | Immunosuppressant drug extraction reagent for immunoassays |
| AU2007286176B2 (en) | 2006-08-11 | 2012-10-11 | Monsanto Technology Llc | Production of high tryptophan maize by chloroplast targeted expression of anthranilate synthase |
| ME01786B (me) | 2006-08-14 | 2014-09-20 | Xencor Inc | Optimizovana antitela usmerena na cd19 |
| MY161894A (en) * | 2006-09-08 | 2017-05-15 | Abbvie Bahamas Ltd | Interleukin-13 binding proteins |
| US20080075690A1 (en) | 2006-09-22 | 2008-03-27 | Mark Douglas Howell | Method for enhancing immune responses in mammals |
| US7750124B2 (en) | 2006-09-29 | 2010-07-06 | Oncomed Pharmaceuticals, Inc. | Anti-human DLL4 antibodies and compositions |
| US20080102475A1 (en) | 2006-10-13 | 2008-05-01 | Zhengyan Kan | Alternatively spliced isoform of phosphodiesterase 4B (PDE4B) |
| KR20090101893A (ko) | 2006-10-27 | 2009-09-29 | 애보트 바이오테크놀로지 리미티드 | 결정형 항-ｈＴＮＦ알파 항체 |
| CN106084054A (zh) * | 2006-11-02 | 2016-11-09 | 健泰科生物技术公司 | 人源化的抗‑d因子抗体 |
| EP2120996A2 (en) | 2006-12-20 | 2009-11-25 | Vasgene Therapeutics, Inc. | Methods for using and identifying modulators of delta-like 4 |
| EP2069404B1 (en) * | 2007-02-14 | 2011-01-05 | Vaccinex, Inc. | Humanized anti-cd100 antibodies |
| HRP20131113T1 (hr) | 2007-02-16 | 2014-01-17 | Merrimack Pharmaceuticals, Inc. | Protutijela protiv erbb3 i njihova uporaba |
| PL2125894T3 (pl) * | 2007-03-22 | 2019-08-30 | Biogen Ma Inc. | Białka wiążące, w tym przeciwciała, pochodne przeciwciał i fragmenty przeciwciał, które swoiście wiążą się z CD154 i ich zastosowania |
| US7906293B2 (en) | 2007-04-09 | 2011-03-15 | Abbott Laboratories | Acridinium phenyl esters useful in the analysis of biological |
| RU2009140134A (ru) * | 2007-04-23 | 2011-05-27 | Вайет (Us) | Способы и композиции для лечения и мониторинга лечения связанных с ил-13 нарушений |
| GB0708002D0 (en) * | 2007-04-25 | 2007-06-06 | Univ Sheffield | Antibodies |
| EP1997832A1 (en) | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
| US8158124B2 (en) | 2007-05-30 | 2012-04-17 | Lpath, Inc. | Compositions and methods for binding lysophosphatidic acid |
| WO2009003142A1 (en) * | 2007-06-27 | 2008-12-31 | The Board Of Trustees Of The Leland, Stanford Junior University | Beta2-microglobulin and c reactive protein (crp) as biomarkers for peripheral artery disease |
| EP2626371A1 (en) * | 2007-07-31 | 2013-08-14 | MedImmune, LLC | Multispecific epitope binding proteins and uses thereof |
| SG183709A1 (en) * | 2007-08-08 | 2012-09-27 | Abbott Lab | Compositions and methods for crystallizing antibodies |
| WO2009021754A2 (en) * | 2007-08-15 | 2009-02-19 | Bayer Schering Pharma Aktiengesellschaft | Monospecific and multispecific antibodies and method of use |
| CA2702590A1 (en) | 2007-10-19 | 2009-04-23 | Abbott Laboratories | Glycosylated mammalian ngal and use thereof |
| BRPI0822049B1 (pt) | 2007-12-17 | 2021-11-16 | Pfizer Limited | Composiqao farmaceutica compreendendo anticorpo antagonista anti-ngf, kit e uso de um anticorpo antingf |
| PT2235064E (pt) | 2008-01-07 | 2016-03-01 | Amgen Inc | Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática |
| US8962803B2 (en) * | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
| JP5470817B2 (ja) | 2008-03-10 | 2014-04-16 | 日産自動車株式会社 | 電池用電極およびこれを用いた電池、並びにその製造方法 |
| CN102076355B (zh) * | 2008-04-29 | 2014-05-07 | Abbvie公司 | 双重可变结构域免疫球蛋白及其用途 |
| KR101603917B1 (ko) | 2008-05-09 | 2016-03-17 | 애브비 인코포레이티드 | 최종 당화 산물의 수용체(ｒａｇｅ)에 대한 항체 및 이의 용도 |
| SG191639A1 (en) | 2008-06-03 | 2013-07-31 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| AU2009256246B2 (en) | 2008-06-03 | 2013-07-18 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| US8741287B2 (en) | 2008-06-18 | 2014-06-03 | Abbott Laboratories | PlGF-1 assay and kits and components thereof |
| BRPI0915825A2 (pt) * | 2008-07-08 | 2015-11-03 | Abbott Lab | proteínas de ligação à prostaglandina e2 usos das mesmas |
| AU2009268585C1 (en) | 2008-07-08 | 2014-10-02 | Abbvie Inc. | Prostaglandin E2 dual variable domain immunoglobulins and uses thereof |
| WO2010017103A2 (en) * | 2008-08-04 | 2010-02-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Fully human anti-human nkg2d monoclonal antibodies |
| CN102227638B (zh) * | 2008-09-30 | 2015-05-20 | Abbvie公司 | Rna展示的改良方法 |
| SG171812A1 (en) | 2008-12-04 | 2011-07-28 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| PE20160653A1 (es) | 2009-03-05 | 2016-07-24 | Abbvie Inc | Proteinas de union a il-17 |
| JP2012525441A (ja) | 2009-05-01 | 2012-10-22 | アボット・ラボラトリーズ | 二重可変ドメイン免疫グロブリンおよびこの使用 |
| AU2010242830C1 (en) | 2009-05-01 | 2014-02-13 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| TW201109438A (en) | 2009-07-29 | 2011-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| PE20121647A1 (es) | 2009-08-29 | 2012-12-31 | Abbvie Inc | Proteinas terapeuticas de union a dll4 |
| TW201119673A (en) * | 2009-09-01 | 2011-06-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| US20110172398A1 (en) | 2009-10-02 | 2011-07-14 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules for anti-angiogenesis therapy |
| TW201124427A (en) * | 2009-10-15 | 2011-07-16 | Abbott Lab | IL-1 binding proteins |
| UY32948A (es) * | 2009-10-15 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| UY32979A (es) * | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| WO2011084714A2 (en) | 2009-12-17 | 2011-07-14 | Biogen Idec Ma Inc. | STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF |
| SG10201501562VA (en) * | 2010-03-02 | 2015-04-29 | Abbvie Inc | Therapeutic dll4 binding proteins |
| PE20130614A1 (es) | 2010-06-24 | 2013-07-01 | Abbvie Inc | Inmunoglobulinas con dominio variable dual y su uso |
| UY33492A (es) * | 2010-07-09 | 2012-01-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| TW201206473A (en) * | 2010-08-03 | 2012-02-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| CN103260639A (zh) * | 2010-08-26 | 2013-08-21 | Abbvie公司 | 双重可变结构域免疫球蛋白及其用途 |
| MX2013004979A (es) | 2010-11-02 | 2013-07-30 | Abbott Lab | Inmunoglobulinas de dominio variable doble y usos de las mismas. |
| AR083705A1 (es) | 2010-11-04 | 2013-03-13 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| JP2014533659A (ja) * | 2011-10-24 | 2014-12-15 | アッヴィ・インコーポレイテッド | スクレロスチンに対するイムノバインダー |
| WO2013102042A2 (en) * | 2011-12-30 | 2013-07-04 | Abbvie Inc. | Dual specific binding proteins directed against il-13 and/or il-17 |
| AU2012362370A1 (en) * | 2011-12-30 | 2014-07-24 | Abbvie Inc. | Dual variable domain immunoglobulins against receptors |
| US20130171059A1 (en) * | 2011-12-30 | 2013-07-04 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| JP6136279B2 (ja) | 2013-01-15 | 2017-05-31 | 株式会社ジェイテクト | 転がり軸受装置 |
| TWI503850B (zh) | 2013-03-22 | 2015-10-11 | Polytronics Technology Corp | 過電流保護元件 |
| TWI510996B (zh) | 2013-10-03 | 2015-12-01 | Acer Inc | 控制觸控面板的方法以及使用該方法的可攜式電腦 |
| US9816280B1 (en) | 2016-11-02 | 2017-11-14 | Matthew Reitnauer | Portable floor |
-
2009
- 2009-04-28 CN CN200980125167.8A patent/CN102076355B/zh not_active Expired - Fee Related
- 2009-04-28 WO PCT/US2009/041945 patent/WO2009134776A2/en not_active Ceased
- 2009-04-28 JP JP2011507576A patent/JP5646457B2/ja not_active Expired - Fee Related
- 2009-04-28 EP EP09739578A patent/EP2282769A4/en not_active Withdrawn
- 2009-04-28 AU AU2009241589A patent/AU2009241589B2/en not_active Ceased
- 2009-04-28 BR BRPI0910482A patent/BRPI0910482A2/pt not_active IP Right Cessation
- 2009-04-28 EP EP15153941.8A patent/EP2899209A1/en not_active Withdrawn
- 2009-04-28 MX MX2010011955A patent/MX2010011955A/es active IP Right Grant
- 2009-04-28 CA CA2722466A patent/CA2722466A1/en active Pending
- 2009-04-28 NZ NZ588554A patent/NZ588554A/xx not_active IP Right Cessation
- 2009-04-28 KR KR1020107026459A patent/KR20110014607A/ko not_active Withdrawn
- 2009-04-28 SG SG2013030655A patent/SG190572A1/en unknown
- 2009-04-28 US US12/431,460 patent/US9029508B2/en active Active
- 2009-04-29 TW TW98114240A patent/TW200950805A/zh unknown
- 2009-04-29 CL CL2009001033A patent/CL2009001033A1/es unknown
- 2009-04-29 UY UY31792A patent/UY31792A/es not_active Application Discontinuation
- 2009-04-29 PE PE2009000578A patent/PE20091845A1/es not_active Application Discontinuation
- 2009-04-29 AR ARP090101544 patent/AR071526A1/es not_active Application Discontinuation
-
2010
- 2010-10-13 IL IL208693A patent/IL208693A0/en unknown
- 2010-10-27 DO DO2010000325A patent/DOP2010000325A/es unknown
- 2010-10-28 EC ECSP10010580 patent/ECSP10010580A/es unknown
- 2010-10-28 CO CO10134183A patent/CO6331296A2/es not_active Application Discontinuation
- 2010-11-17 CR CR11795A patent/CR11795A/es not_active Application Discontinuation
-
2014
- 2014-05-13 JP JP2014099291A patent/JP2014193170A/ja active Pending
- 2014-06-10 US US14/301,305 patent/US20150104452A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011523400A5 (enExample) | ||
| JP2011523853A5 (enExample) | ||
| JP2012500621A5 (enExample) | ||
| JP2011527580A5 (enExample) | ||
| JP2013500721A5 (enExample) | ||
| JP2013507969A5 (enExample) | ||
| JP2013537415A5 (enExample) | ||
| JP2012525441A5 (enExample) | ||
| JP2013503607A5 (enExample) | ||
| JP2013507928A5 (enExample) | ||
| JP2013509189A5 (enExample) | ||
| RU2011104348A (ru) | Иммуноглобулины с двойным вариабельным доменом против простагландина е2 и их применение | |
| JP2013539364A5 (enExample) | ||
| JP2014504860A5 (enExample) | ||
| RU2012121189A (ru) | Иммуноглобулины с двумя вариабельными доменами и их применение | |
| JP2012525155A5 (enExample) | ||
| RU2012107526A (ru) | Иммуноглобулины с двумя вариабельными доменами и их применение | |
| RU2015143833A (ru) | СВЯЗЫВАЮЩИЕ БЕЛКИ С ДВОЙНОЙ СПЕЦИФИЧНОСТЬЮ, НАПРАВЛЕННЫЕ ПРОТИВ TNFα | |
| RU2013133811A (ru) | Иммуноглобулины с двойными вариабельными доменами и их применения | |
| RU2013109275A (ru) | Иммуноглобулины с двумя вариабельными доменами и их применение | |
| RU2012119756A (ru) | Иммуноглобулины с двумя вариабельными доменами и их применение | |
| JP2012519708A5 (enExample) | ||
| RU2013105338A (ru) | Иммуноглобулины с двумя вариабельными доменами и их применение | |
| RU2011104228A (ru) | Белки, связывающие простагландин e2, и их применение | |
| RU2010153580A (ru) | Иммуноглобулины с двумя вариабельными доменами и их применение |